# Patent

## Title
Polyamine derivatives as radioprotective agents

## Abstract

Inhibitors of the sodium-hydrogen exchanger are suitable on their own or in combination with other classes of active compound for the production of a medicament for the treament of diseases which are caused by protozoa; thus of diseases which are caused by animal- and human-pathogenic protozoa, such as by intracellularly active parasites of the classes Apicomplexa and Zoomastigophorea, in particular trypanosomes, plasmodia (malaria pathogens), leishmanias, babesias and theilerias, cryptosporidiidae, sarcocystidae, amoebae, coccidia and trichomonads. NHE inhibitors are particularly preferably suitable for the production of a medicament for the treatment of tropical malaria, of tertian malaria, of quartan malaria, as well as toxoplasmosis, of coccidiosis, of intestinal sarcosporidosis, of cryptosporidosis, of Chargas' disease and of the cutaneous and visceral as well as other forms of leishmaniases; and also for the production of a medicament for the treatment of animals which have been infected by animal-pathogenic protozoa, such as by Theileria parva, the pathogen of East Coast fever of cattle, Babesia begemina, the pathogen of Texas fever in cattle and buffalo, Babesia bovis, the pathogen of European bovine babesiosis, and babesioses in dogs, cats and sheep, sarcocystidae, the pathogens of sarcocystoses in sheep, cattle and pigs, cryptosporidiidae, the pathogens of cryptosporidosis in cattle and birds, coccidia, the pathogens of coccidioses of rabbits, cattle, sheep, goats and pigs, but in particular of chickens and turkeys.

## Background
Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa.

The invention relates to the use of inhibitors of the cellular sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of diseases which occur as a result of attack of humans and animals by protozoa.

Inhibitors of the sodium-hydrogen exchanger (NHE) have in recent years been characterized in numerous preclinical studies as substances which in the case of restricted circulation of the heart are suitable in a superior manner to protect endangered heart tissue from death. The protection of the heart tissue in this case includes all forms of heart damage caused by inadequate circulation, starting with cardiac arrhythmias via hypercontraction of the heart muscle and temporary loss of function up to death of the heart tissue and permanent damage associated therewith.

The mechanism of action of the NHE inhibitors is that they decrease the increased influx of sodium ions which arises in inadequately supplied tissues as a result of intracellular acidification and subsequent activation of the NHE. Since sodium and calcium ion transport are coupled to one another in mammalian tissue, the life-threatening calcium overloading of the cells is thus also prevented. This unique mechanism relates relatively specifically, in particular, to heart tissue.

It was therefore surprising, as could now be found, that NHE inhibitors are able to kill protozoa having a pathogenic action on humans and animals or to significantly restrict the survival ability of protozoa. Inhibitors of the sodium-hydrogen exchanger are therefore suitable on their own or in combination with other classes of active compound for the treatment of diseases which are caused by protozoa.

Animal- and human-pathogenic protozoa of this type are preferably intracellularly active parasites of the classes Apicomplexa and Zoomastigophorea, in particular trypanosomes, plasmodia (malaria pathogens), leishmanias, babesias and theilerias, cryptosporidiidae, sarcocystidae, ameeba, coccidia and trichomonads.

Particularly preferably, NHE inhibitors are suitable for the treatment of tropical malaria, which is caused by Plasmodium falciparum, for the treatment of tertian malaria, induced by Plasmodium vivax and Plasmodium ovale, for the treatment of quartan malaria, caused by Plasmodium malariae, and for the treatment of toxoplasmosis, caused by Toxoplasma gondii, of coccidiosis, caused by Isospora belli, of intestinal sarcosporidosis, caused by Sarcocystis suihominis, of cryptosporidosis, caused by Cryptosporidium parvum, of Chargas' disease, which is caused by Trypanosoma cruzi, of the cutaneous and visceral and also other forms of leishmaniases, and also for the treatment of animals which have been infected by animal-pathogenic protozoa, such as by Theileria parva, the pathogen of East Coast fever of cattle, Babesia begemina, the pathogen of Texas fever in cattle and buffalo, Babesia bovis, the pathogen of European bovine babesiosis, and also babesiosis in dogs, cats and sheep, sarcocystidae, the pathogens of sarcocystoses in sheep, cattle and pigs, cryptosporidiidae, the pathogens of cryptosporidosis in cattle and birds, coccidia, the pathogens of coccidioses of rabbits, cattle, sheep, goats and pigs, but in particular of chickens and turkeys.

In the treatment of diseases which are caused by human- and animal-pathogenic protozoa, the NHE inhibitors can be administered both orally and parenterally. In this case, NHE inhibitors are used as monosubstances and in combination with other active compounds. Since with NHE a novel principle of action is concerned, combinations with pharmaceuticals which are already used for the treatment of the respective protozoa-related disorder are also advantageously utilizable, a favorable, additively reinforcing action being observed.

Very particularly preferably, the NHE inhibitors are suitable for the treatment of forms of malaria, in particular for the treatment of malaria tropica. At present, between 300-500 million people suffer from malaria, and every twelve seconds a person dies from the consequences of this infectious disease. The number of cases of malaria will in-all probability increase still further in the next few years, since effective methods for the control of malaria are lacking at present. Medicaments which have been employed up to now against malaria have largely lost their efficacy. The malaria pathogens, protozoa of the genus Plasmodium, have become resistant. In order to avert the impending catastrophe, according to the World Health Organization novel pharmaceuticals are urgently needed for the prophylactic and curative treatment of malaria. In this connection, the development of novel medicaments against malaria has proven to be very difficult.

It was therefore surprising that NHE inhibitors have proven effective not only against chloroquine-sensitive but also against chloroquine-resistant Plasmodium falciparum strains. In addition to the treatment of the later erythrocytic stage of the malaria pathogen, which was customary up to now, with NHE inhibitors the treatment of the early form of malaria also appears to be very particularly advantageous due to destruction of the pathogens even in the liver.

In what follows, the activity of NHE inhibitors against protozoa is described:

Culture of Plasmodium falciparum

Erythrocytic stages of the human malaria parasite Plasmodium falciparum were cultured in RPMI 1640 medium, with L-glutamine, 25 mM HEPES, 4 .mu.g/ml of gentamycin, 10% human serum and 5% human erythrocytes, according to Trager and Jensen (1976). The cultures were kept in Petri dishes (10 ml per dish with 10 cm diameter) and incubated at 37.degree. C. in an atmosphere of 92% nitrogen, 3% carbon dioxide and 5% oxygen. The medium of the cultures was changed daily. At a parasitemia of at most 10%, the cultures were diluted. In order to synchronize the cultures, the infected erythrocytes were washed in 5% strength sorbitol solution according to Lambros and Vanderberg (1979). Only the ring stages survive this treatment.

Determination of the IC.sub.50 values of the various NHE inhibitors

The half-maximal inhibitory concentration of various NHE inhibitors for the growth of Plasmodium flaciparum was measured in 96-well microtiter plates by incorporation of radioactive hypoxanthine according to Desjardins et al. (1979). In this case, the parasites were cultured for a complete erythrocyte cycle lasting 48 hours in the presence of the corresponding NHE inhibitors.

The NHE inhibitors were dissolved in DMSO and prediluted in physiological saline solution (150 mM NaCl). The dilution series of the NHE inhibitors in 10-fold concentrated 20 .mu.l aliquots was initially introduced onto the microtiter plates, 180 .mu.l of parasite suspension in culture medium were then added to each one. The parasites were in the ring stage with a parasitemia of 1%. The microtiter plates were then incubated for 24 hours. In order to change the culture medium, 150 .mu.l each of supernatant from each well were removed and replaced by 135 .mu.l of new medium, additionally supplemented with 2 .mu.Ci/ml of [3H]-hypoxanthine. The concentration of the NHE inhibitors was again adjusted by adding 10-fold concentrated stock solutions in 15 .mu.l aliquots. After incubation for a further 24 hours, the cultures were harvested by filtration on glass fiber filters and the incorporated radioactivity was measured. The percentage inhibition of the tritium incorporation was related to a control without NHE inhibitor.

The IC.sub.50 values of the various NHE inhibitors were measured on a chloroquine-sensitive (HB3) and a chloroquine-resistant (Dd2) strain. Substance        HB3 IC.sub.50 [.mu.m] Dd2 IC.sub.50 [.mu.m] ______________________________________ 3-trifluoromethyl-5-N,N- 9,97 .+-. 0.12 1.3 .+-. 0.10 dimethylaminobenzoylguanidine dihydrochloride 3-trifluoromethyl-4-(3-  12 .+-. 1.7 6.5 .+-. 1.5 pyridyloxy)benzoylguanidine dihydrochloride 4-[4-(2-aminoethyl)phenoxy]-3-  2.9 .+-. 0.79 3.5 .+-. 0.04 methylsulfonylbenzoylguanidine dihydrochloride ______________________________________

Desjardins, R. E., Canfield, C. J. Haynes, J. D. and Chulay, J. D. (1979) Quantitative assessment of antimalarial activity in vitro by semiautomated microdilution technique, Antimicrob. Agents Chemother. 16: 710-718.

Lambros, C. J. and Vanderberg, J. (1979) Synchronization of Plasmodium falciparum erythrocytic stages in culture, J. Parasitol. 65: 418-420.

Trager, W. and Jensen, J. B. (1976) Human malaria parasites in continuous culture. Science 193: 673-675

The active compounds known and identified as NHE inhibitors are guanidine derivatives, preferably acylguanidines, inter alia as described in the following publications and patent disclosures: Edward J. Cragoe, Jr., "DIURETICS, Chemistry, Pharmacology and Medicine", J. WILEY & Sons (1983), 303-341, additionally compounds of the following formulae:

1. (HOE 89/F 288--U.S. Pat. No. 5,292,755) ##STR1## in which: R(1) or R(2) is R(6)--S(O).sub.n -- or R(7)R(8)N--O.sub.2 S--; (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy or phenoxy, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy; R(7)R(8)N--; cyclopentylmethyl, cyclohexylmethyl or phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy; or selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -C.sub.7)-chain, where the chain can additionally be interrupted by O, S or NR(9); a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; -C.sub.2)-alkyl, or

and their pharmaceutically tolerable salts;

(HOE 92/F 34 - U.S. Pat. No. 5,373,924) ##STR2## in which: R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by an O, S, NH, N--CH.sub.3 or N-benzyl; C.sub.p F.sub.2p+1 or--X--R(10); cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl; trifluoromethyl, F, Cl, Br, I or --X--R(10); cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy und NR(8)R(9); group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl;

and their pharmaceutically tolerable salts;

(HOE 92/F 035 EP-A 556 673) ##STR3## in which: R(1) is F, Cl, Br, I, C.sub.1 -C.sub.6 -alkyl or --X--R(6); cyclohexylmethyl, cyclopentylmethyl, --(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --C.sub.n H.sub.2n --R(8); selected from the group consisting of the groups F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl; cyclohexylmethyl, cyclopentylmethyl, --(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --C.sub.n H.sub.2n --R(8); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl; R(12)R(13)N--SO.sub.2 --; as a substituent, where phenyl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); salts;

(HOE 92/F 036 - U.S. Pat. No. 5,364,868) ##STR4## in which: R(1) or R(2) is an amino group --NR(3)R(4); C.sub.3 -C.sub.7 -cycloalkyl; or one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -methylene chain, where one --CH.sub.2 -- member of the methylene chain can be replaced by oxygen, S or NR(5); -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, CF.sub.3, C.sub.m F.sub.2m+1 --CH.sub.2 --, benzyl or phenoxy, substituents selected from the group consisting of methyl, methoxy, fluorine and chlorine;

and their pharmaceutically tolerable salts;

(92/F 197 K - NZ 248 013) ##STR5## in which: R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by an O, S, NH, N--CH.sub.3 or N-benzyl; --CR(13).dbd.CHR(12) or --C.tbd.CR(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); substituted as phenyl, or 1-3 OH, or -C.sub.8)-cycloalkyl-(C.sub.1 -C.sub.4)-alkyl, phenyl, C.sub.6 H.sub.5 -(C.sub.1 -C.sub.4)-alkyl, naphthyl, biphenylyl, 1,1-diphenyl-(C.sub.1 -C.sub.4)-alkyl, cyclopentadienyl, pyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indazolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl; are unsubstituted or substituted by 1-3 substituents from the groups F, Cl, CF.sub.3, (C.sub.1 -C.sub.4)-alkyl or -alkoxy, or NR(10)R(11) with R(10) and R(11) being H or (C.sub.1 -C.sub.4)-alkyl;

and their pharmaceutically tolerable salts;

(HOE 92/F 303 K - EP-A 589 336, NZ 248 703) ##STR6## in which: R(1) or R(2) is R(3)--S(O).sub.n -- or R(4)R(5)N--SO.sub.2 -- the other substituent R(1) or R(2) in each case is H, OH, F, Cl, Br, I, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, benzyloxy or phenoxy, the group consisting of fluorine, chlorine, methyl, methoxy, hydroxyl or benzyloxy, cyclopentylmethyl, cyclohexylmethyl or phenyl, the group consisting of fluorine, chlorine, methyl and methoxy; or selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -chain, where the chain can additionally be interrupted by O, S or NR(6), a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;

and their pharmaceutically tolerable salts;

(92/F 304 - U.S. Pat. No. 5,416,094) ##STR7## in which: R(1) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring; from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, trifluoromethyl, consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, ##STR8## X(2), X(3) and X(4) independently of one another are hydrogen, halogen, nitro, amino, alkyl, sulfonamide, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, benzyloxy, hydroxyl; aminoalkyl or an aryl or a heteroaryl ring; the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl; by oxygen, sulfur or NR(8); aminoalkyl or an aryl or heteroaryl ring, which rings are unsubstituted or substituted by 1-3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl;

and their pharmaceutically acceptable salts;

(92/F 404 - EP 602 522, NZ 250 438) ##STR9## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.tbd.N, --CF.sub.3, R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; --[CR(12)R(13)OR(13')], --{C-[CH.sub.2 --OR(13')]R(12) (R(13)} or --[CR(18)R(17)].sub.p --(CO)--[CR(19)R(20)].sub.q --R(14); --(CH.sub.2).sub.p --(CHOH)q--(CH2).sub.r --(CHOH).sub.t --R(21) or --(CH.sub.2).sub.p --O--(CH.sub.2 --CH.sub.2 O).sub.q --R(21), R(21) is hydrogen, methyl, p, q, r identically or differently are zero, 1, 2, 3 or 4; -C.sub.6)-alkyl or, together with the carbon atom carrying them, are a (C.sub.3 -C.sub.8)-cycloalkyl, --C.sub.a H.sub.2a --R(15); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); substituted as phenyl, or 1-3 OH; group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

and their pharmaceutically tolerable salts;

(HOE 92/F 405 - EP 602 523, NZ 250 437) ##STR10## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.tbd.N, R(16)--C.sub.p H.sub.2p --O.sub.q, R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; --C.sub.b H.sub.2b --R(15); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9);

and their pharmaceutically tolerable salts;

(HOE 92/F 411 - NZ 250 450, EP 603 650) ##STR11## in which: one of the substituents R(1), R(2), R(3) or R(4): ##STR12## R(5) is hydrogen or C.sub.(1-6) -alkyl; n is zero, 1, 2, 3 or 4; replaced by 1 sulfur atom or a group NR(7); carries 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, methyl, methoxy, --NR(8)R(9); ring, in which 1 carbon atom can be replaced by oxygen, S or NR(10);

and the other substituents R(1), R(2), R(3), R(4) in each case are: F.sub.2m+1 --CH.sub.2 --O-- or R(11)--C.sub.q H.sub.2q --X.sub.p --; which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH.sub.3, CH.sub.3 --O-- and NR(13)R(14);

and their pharmaceutically tolerable salts;

(HOE 92/F 422 - EP 604 852) ##STR13## in which R(1) is R(4)R(5)N--C(X)--; (C.sub.3 -C.sub.6)-alkenyl or --C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; (C.sub.3 -C.sub.8)-cycloalkyl, (C.sub.3 -C.sub.8)-cycloalkyl-(C.sub.1 -C.sub.4)-alkyl, phenyl, C.sub.6 H.sub.5 -(C.sub.1 -C.sub.4)-alkyl, naphthyl, biphenylyl, 1,1-diphenyl-(C.sub.1 -C.sub.4)-alkyl, cyclopentadienyl, pyridyl, thiopyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl or --W--R(8); cyclohexylmethyl, cyclopentylmethyl, --(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --C.sub.q H.sub.2q --R(10); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(11)R(12); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; for R(2), and their pharmaceutically acceptable salts;

(93/F 054 - NZ 250 919, EP-A 612 723) ##STR14## in which: R(1), R(2), R(3) are hydrogen, F, Cl, Br, I or (C.sub.1 -C.sub.12)-alkyl; -C.sub.10)-alkyloxy, if at least one of the remaining substituents R(1), R(2) or R(3) is a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms; or --O.sub.m --; isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted by a substituent selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(5)R(6);

or one of the substituents R(1), R(2) or R(3) is --C.tbd.CR(5) or --C[R(6)].dbd.CR(5); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, hydroxyl, amino, methylamino and dimethylamino, (C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted as phenyl, or 1-3 OH; or

and their pharmacologically acceptable salts;

(93/F 153 - EP-A 627 413, NZ 260 660) ##STR15## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.tbd.N, X.sub.o --(CH.sub.2).sub.p --(CF.sub.2).sub.q --CF.sub.3, R(5)--SO.sub.m, R(6)--CO-- or R(6)R(7)N--SO.sub.2 --, where -C.sub.n H.sub.2n --R(8) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; ##STR16## Y is oxygen, --S-- or --NR(12)--; R(11) and R(12) are hydrogen or (C.sub.1 -C.sub.3)-alkyl; not simultaneously zero, H.sub.2b --R(15); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10);

and their pharmaceutically tolerable salts;

(HOE 93/F 154 - EP-A 628 543, NZ 260 681) ##STR17## in which: R(1) is R(6)--CO or R(7)R(8)N--CO; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(9); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(10)R(11); -C.sub.4)-perfluoro-alkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(12); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoro-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n R(15); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); -C.sub.4)-perfluoro-alkyl; or is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or (C.sub.3 -C.sub.8)-alkenyl, --C.sub.n H.sub.2n --R(24), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); -C.sub.4)-perfluoro-alkyl; (C.sub.3 -C.sub.8)-alkenyl, --C.sub.n H.sub.2n --R(29); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(30)R(31); -C.sub.4)-perfluoro-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or (CH.sub.2).sub.b C.sub.d F.sub.2d+1, --C.sub.n H.sub.2n --R(36), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(37)R(38); -C.sub.4)-perfluoro-alkyl; group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; benzoylguanidine parent structure; or --C[R(42)R(43)OH], --C.tbd.CR(45), --CR(46).dbd.CHR(45), --[CR(47)R(48)].sub.u --(CO)--[CR(49)R(50)].sub.v --R(44); --(CHOH).sub.q --(CH.sub.2).sub.r --(CHOH).sub.t --R(51) or --(CH.sub.2).sub.p --O--(CH.sub.2 --CH.sub.2 O)q.sub. --R(51); -C.sub.6)-alkyl; or -C.sub.8)-cycloalkyl; H.sub.2e --R(45); from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53) where R(52) and R(53) are H or (C.sub.1 -C.sub.4)-alkyl, or R(45) is (C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted as phenyl; or 1-3 OH; (C.sub.3 -C.sub.6)-alkenyl or --C.sub.f H.sub.2f --R(59); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; R(2);

and their pharmaceutically tolerable salts;

(HOE 93/F 220 - EP-A 640 593, NZ 264 117) ##STR18## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.tbd.N, --X.sub.o --(CH.sub.2).sub.p --(CF.sub.2).sub.q --CF.sub.3, R(5)--SO.sub.m --, R(6)--CO--, R(6)R(7)N--CO-- or R(6)R(7)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(8) or CF.sub.3 ; is substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; ##STR19## R(11) is (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl; --C.sub.b H.sub.2b --R(15); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10);

and their pharmaceutically tolerable salts;

(HOE 93/F 223 K - EP 639 573, NZ 264 130) ##STR20## in which: X is N or CR(6); the substituents R(1) to R(6) is a --CO--N.dbd.C(NH.sub.2).sub.2 group; or (C.sub.1 -C.sub.6)-alkyl; (C.sub.1 -C.sub.4)-alkyloxy or CF.sub.3 ; straight-chain or branched and where one carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom; -C.sub.10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group --CH.dbd.CH--, and in which one methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom; or substituents selected from the group consisting of F, Cl, Br, I, CF.sub.3, CH.sub.3 --S(O).sub.s -- or R(9)--W.sub.y --; R(8)--C.sub.n H.sub.2n --;

and their pharmaceutically tolerable salts;

(HOE 93/F 236 - EP-A 638 548, NZ 264 216) ##STR21## in which: R(1), R(3) or R(4) is --NR(6) C.dbd.X NR(7)R(8); -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(9); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(10)R(11); -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.o H.sub.2o --R(12); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl; group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

the remaining substituents R(2), R(3), R(4), R(5) or R(1), R(2), R(4), R(5) or R(1), R(2), R(3), R(5) in each case independently of one another are hydrogen, F, Cl, Br, I, --O.sub.ta (C.sub.1 -C.sub.8)-alkyl, --O.sub.tb (C.sub.3 -C.sub.8)-alkenyl, --O.sub.tc (CH.sub.2).sub.b C.sub.d F.sub.2d+1, --O.sub.td C.sub.p H.sub.2p R(18), or up to 2 groups CN, NO.sub.2, NR(16)R(17), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(19)R(20); -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, --c.sub.q H.sub.2q --R(.sup.2 1), where the aromatics are not substituted or are substituted by 1-3 substituents from the group F, Cl, CF.sub.3, methyl, methoxy or NR(22)R(23), R(22) and R(23) are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, --C.sub.r H.sub.2r --R(24); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

and their pharmaceutically tolerable salts;

(HOE 93/F 249 - EP-A 640 587, NZ 264 282) ##STR22## in which: X(1) and X(2) are ##STR23## T1 is zero, 1, 2, 3 or 4; R(A) and R(B) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(106), (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.zk (CH.sub.2).sub.zl C.sub.zm F.sub.2zm+1, NR(107)R(108), phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(109)R(110); -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(111)R(112); -C.sub.4)-perfluoro-alkyl; CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or ##STR24## T2a and T2b independently of one another are zero, 1 or 2; where the double bond can have the (E)- or (Z)-configuration; or ##STR25## T3 is zero, 1 or 2; U, YY and Z independently of one another are C or N, where U, YY, Z can carry the following number of substituents: Bonded in the ring to Number of permitted U, YY or Z a double bond substituents ______________________________________ C          yes           1 C no 2 N yes 0 N no 1 ______________________________________ -C.sub.8)-perfluoroalkyl, R(U1), R(U2), R(Y1), R(Y2), R(Z1), R(Z2) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(114), (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.zka (CH.sub.2).sub.zla C.sub.zma F.sub.2zma+1, NR(115)R(116), phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, NR(117)R(118), R(117) and R(118) are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl, -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(119)R(120); -C.sub.4)-perfluoro-alkyl; CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; but where the constitution of U is nitrogen (N), YY is nitrogen (N) and Z is carbon (C) is excluded, hydrogen, F, Cl, Br, I, --C.tbd.N, X.sub.zoa --(CH.sub.2).sub.zpa --(C.sub.zqa F.sub.2zqa+1), R(110a)--SO.sub.zbm, R(110b)R(110c) N--CO, R(111a)--CO-- or R(112a)R(113a)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-alkenyl, --C.sub.zn H.sub.2zn --R(115a) or (C.sub.1 -C.sub.8)-perfluoroalkyl; where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(116a)R(117a); (C.sub.1 -C.sub.4)-alkyl; or -C.sub.4)-perfluoroalkyl or (C.sub.1 -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or (C.sub.1 -C.sub.8)-alkyl, --C.sub.zal H.sub.2zal R(118a) or (C.sub.3 -C.sub.8)-alkenyl, where the aromatics are not substituted or are substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(119a)R(119b); -C.sub.4)-perfluoroalkyl; or (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --C.tbd.C--R(193); substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(194)R(195); --(CH.sub.2).sub.zj --(CHOH).sub.zk --R(123), --(CH.sub.2).sub.zaf --(CHOH).sub.zag --R(124) or --(CH.sub.2).sub.zap --(CHOH).sub.zak --R(125); or 4; and zag are not simultaneously zero, and zah, zao and zak are not simultaneously zero, -C.sub.3)-alkyl; or SR(129), --OR(130), --NR(131 )R(132) or --CR(133)R(134)R(135); --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; R(129) or are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or --W--para--(C.sub.6 H.sub.4)--R(196), --W--meta--(C.sub.6 H.sub.4)--R(197) or --W--ortho--(C.sub.6 H.sub.4)--R(198); which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl; R(1 46)X(1a)--; C.sub.zdz F.sub.2zdz+1 or --C.sub.zxa H.sub.2zxa --R(151); where the aromatics are not substituted or are substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(152)R(153); -C.sub.4)-perfluoroalkyl; -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-perfluoroalkyl; groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; parent structure; or --SR(164), --OR(165), --NHR(166), --NR(167)R(168), --CHR(169)R(170), --CR(154)R(155)OH, --C.tbd.CR(156), --CR(158).dbd.CR(157) or --[CR(159)R(160)].sub.zu --(C.dbd.O)--[CR(161)R(162)].sub.zv --R(163); --(CH.sub.2).sub.zy --(CHOH).sub.zz --(CH.sub.2).sub.zaa --(CHOH).sub.zt --R(171) or --(CH2).sub.zab --O--(CH.sub.2 --CH.sub.2 O).sub.zac --R(172); (C.sub.1 -C.sub.6)-alkyl, or carrying them are a (C.sub.3 -C.sub.8)-cycloalkyl; or --C.sub.zeb H.sub.2zeb --R(173); or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(174)R(175); which is unsubstituted or substituted as phenyl; R(176)--NH--SO.sub.2 --; -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.zfa H.sub.2zfa --R(180); or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy or (C.sub.1 -C.sub.4)-alkyl; or CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; NR(184a)R(185), OR(184b), SR(184c) or --C.sub.znx H.sub.2znx --R(184d); substituted or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(116k)R(117k); hydrogen, (C.sub.1 -C.sub.8)-alkyl, or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(184u)R(184v); CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl;

and their pharmaceutically tolerable salts;

(HOE 93/F 254 - EP-A 640 588, NZ 264 307) ##STR26## in which: R(1) is H, F, Cl, Br, I, CN, NO.sub.2, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or X.sub.a --(CH.sub.2)b--(CF.sub.2).sub.c --CF.sub.3 ; substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); -C.sub.9)-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; or latter linked via C or N, and which are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --C[R(15)R(16)]OH, --C.tbd.CR(18), --C[R(19].dbd.CR(18), --[CR(20)R(21)].sub.k --(CO)--[CR(22)R(23)R(24)].sub.l --(CHOH).sub.h --(CH.sub.2).sub.i --(CHOH).sub.j --R(17), -C.sub.6)-alkyl or together with the carbon atom carrying them are a (C.sub.3 -C.sub.8)-cycloalkyl; substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); substituted as phenyl; or 1 to 3 OH; or --C.sub.m H.sub.2m --R(18); --(CF.sub.2).sub.o --CF.sub.3 ;

and their pharmaceutically tolerable salts;

(HOE 93/F 436 - EP-A 659 748), NZ 270 264) ##STR27## in which: X is carbonyl, sulfonyl, hydroxyl, substituted by 1-3 substituents from the group F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino or dimethylamino,

and their pharmaceutically tolerable salts;

(HOE 94/F 014 K - EP-A 666 252, NZ 270 370) perfluoroalkyl groups, of the formula I ##STR28## in which: R(A) is hydrogen, F, Cl, Br, I, CN, OR(6), (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1 or NR(7)R(8); (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoroalkyl; --O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+1, F, Cl, Br, I or CN;

but with the condition that at least one of the substituents R(1), R(2), R(3), R(4), R(5), R(A) and R(B) is an --O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+1 or an O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1 group, and their pharmaceutically tolerable salts;

(HOE 94/F 094 - EP-A 676 395, NZ 270 894) ##STR29## in which: HA is SO.sub.m, O or NR(5); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(82)R(83); which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; ; -C.sub.3)-alkyl, --OR(6), C.sub.r F.sub.2r+1, --CO--N.dbd.C(NH.sub.2).sub.2 or --NR(6)R(7); --C.tbd.N, X--(CH.sub.2).sub.p --(C.sub.q --F.sub.2q+1), R(.sup.8)--SO.sub.bm, R(9)R(10)N--CO, R(11)--CO-- or R(12)R(13)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched, (C.sub.3 -C.sub.6)-alkenyl, --C.sub.n H.sub.2n --R(15), CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(16)R(17); of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, or --C.sub.al H.sub.2al R(18); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(19)R(20); -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or ##STR30## Y is oxygen, --S-- or --NR(22)--; h, ad, ah independently are zero or 1; where in each case h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, ah, ao and ak are not simultaneously zero, -C.sub.3)-alkyl; or (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.g H.sub.2g R(26); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); -C.sub.4)-pefluoroalkyl; or --NR(31)R(32) or --CR(33)R(34)R(35); --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or ##STR31## R(96), R(97) and R(98) independently are (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl; R(38)R(39)N--SO.sub.2 --; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.s H.sub.2s R(40); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(41)R(42); -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.w H.sub.2w --R(43); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(44)R(45); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or (CH.sub.2).sub.b C.sub.d F.sub.2d+1 or --C.sub.x H.sub.2x --R(51); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53); -C.sub.4)-perfluoroalkyl; or (C.sub.1 -C.sub.4)-perfluoroalkyl; of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, benzoylguanidine parent structure; or --NHR(66), --NR(67)R(68), --CHR(69)R(70), --C(OH)R(54)R(55), --C.tbd.CR(56), --CR(58).dbd.CHR(57), --[CR(59)R(60)].sub.u --(CO)--[CR(61)R(62)].sub.v --R(63); --(CH.sub.2).sub.y --(CHOH).sub.z --(CH.sub.2).sub.aa --(CH.sub.2 OH).sub.t --R(71) or --(CH.sub.2).sub.ab --O--(CH.sub.2 --CH.sub.2 O).sub.ac --R(72), R(71) and R(72) are hydrogen or methyl; (C.sub.1 -C.sub.6)-alkyl; or them are a (C.sub.3 -C.sub.8)-cycloalkyl; --C.sub.e H.sub.2e --R(73); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(74)R(75); which is unsubstituted or substitued as phenyl; (C.sub.3 -C.sub.6)-alkenyl, --C.sub.f H.sub.2f --R(80); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, -C.sub.4)-alkyl, or together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or of which one or two CH.sub.2 groups can be replaced by CH--C.sub.dm H.sub.2dm+1,

and their pharmaceutically tolerable salts;

(HOE 94/F 123 - EP-A 682 017, NZ 272 058) ##STR32## in which: T, U, V, W, X, Y and Z independently of one another are nitrogen or carbon; but with the restriction that X and Z are not simultaneously nitrogen, and that T, U, V, W, X, Y and Z carry no substituents if they are nitrogen, and that no more than four of them are simultaneously nitrogen, (C.sub.1 -C.sub.3)-alkyl, (C.sub.1 -C.sub.3)-perfluoroalkyl, OR(8), NR(8)R(9) or C(.dbd.O)N.dbd.C(NH.sub.2).sub.2 ; -C.sub.3)-alkyl, or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; F, Cl, Br, I, --C.tbd.N, X.sub.k --(CH.sub.2).sub.p --(C.sub.q F.sub.2q+1), R(10a)--SO.sub.bm, R(10b)R(10c)N--CO, R(11)--CO-- or R(12)R(13)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched; -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl, --C.sub.n H.sub.2n --R(15) or (C.sub.1 -C.sub.8)-perfluoroalkyl; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or -C.sub.8)-alkyl, --C.sub.al H.sub.2al R(18) or (C.sub.3 -C.sub.8)-alkenyl; where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(19a)R(19b); -C.sub.4)-perfluoroalkyl; or -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino or dimethylamino; or ##STR33## Y is oxygen, --S-- or --NR(22)--; h, ad, ah independently of one another are zero or 1; 1, 2, 3 or 4; ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero, (C.sub.1 -C.sub.3)-alkyl; or --OR(30), --NR(31)R(32) or --CR(33)R(34)R(35); H.sub.2a --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or ##STR34## R(96), R(97) and R(98) independently of one another are (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstitued or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl; R(46)X(1)--; (CH.sub.2).sub.b C.sub.d F.sub.2d+1 or --C.sub.x H.sub.2x --R(51); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53); -C.sub.4)-perfluoroalkyl; or (C.sub.1 -C.sub.4)-perfluoroalkyl; of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; heteroaroylguanidine parent structure; or --OR(65), --NHR(66), --NR(67)R(68), --CHR(69)R(70) or --CR(54)R(55)OH, --C.tbd.CR(56), --CR(58).dbd.CR(57) or --[CR(59)R(60)].sub.u --CO--[CR(61)R(62)].sub.v --R(63); --(CH.sub.2).sub.y --(CHOH).sub.z --(CH.sub.2).sub.aa --(CHOH).sub.t --R(71) or --(CH.sub.2).sub.ab --O--(CH.sub.2 --CH.sub.2 O).sub.ac --R(72); (C.sub.1 -C.sub.6)-alkyl; or them are (C.sub.3 -C.sub.8)-cycloalkyl; or --C.sub.e H.sub.2e --R(73); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(74)R(75); which is unsubstituted or substituted as phenyl; R(76)--NH--SO.sub.2 --; -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.f H.sub.2f --R(80); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; NR(84a)R(85), OR(84b), SR(84c) or --C.sub.n H.sub.2n --R(84d); or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl or (CH.sub.2).sub.ax R(84g); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(84u)R(84v); CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl,

and their pharmaceutically tolerable salts;

(HOE 94/F 134 - EP-A 686 627, NZ 272 103) ##STR35## in which: R(1) is R(6)--SO.sub.m ; straight-chain or branched; alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, methyl and methoxy; or pyrrol-3-yl, which is not substituted or is substituted by 1 to 4 substituents selected from the group consisting of F, Cl, Br, I, CN, alkanoyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxycarbonyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, formyl, carboxyl, CF.sub.3, methyl and methoxy; or 3 carbon atoms, F, Cl, Br, I, CN, OR(7), NR(8)R(9) or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms;

and their pharmacologically acceptable salts;

(HOE 94/F 168 - EP-A 690 048, NZ 272 373) perfluoroalkyl groups, of the formula I ##STR36## in which R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C.sub.1 -C.sub.8)-alkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, (C.sub.3 -C.sub.8)-cycloalkyl or NR(7)R(8); (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl; where the aromatics are not substituted or are substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoroalkyl; group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; O.sub.p (CH.sub.2).sub.f C.sub.g F.sub.2g+1 or (C.sub.3 -C.sub.8)-cycloalkyl; (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl; where the aromatics phenyl or benzyl are not substituted or are substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; C.sub.e F.sub.2e+1, (C.sub.3 -C.sub.8)-cycloalkyl, F, Cl, Br, I or CN;

but with the condition that at least one of the substituents R(A), R(B), R(C), R(D), R(1), R(2), R(4) or R(5) is an O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, O.sub.p (CH.sub.2).sub.f C.sub.g F.sub.2g+1 or O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+1 group and R(3) is not an O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+1 group;

and their pharmaceutically tolerable salts;

(HOE 94/F 182 - EP-A 690 048, NZ 272 449) ##STR37## in which: R(1) is NR(50)R(6), R(50) and R(6) independently of one another are hydrogen, (C.sub.1 -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-perfluoroalkyl; --, R(11)R(12)N--CO--, R(13)--CO-- or R(14)R(15)N--SO.sub.2 --; are (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.ab H.sub.2ab --R(16); is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(17)R(18); -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or --OR(22), --NR(23)R(24) or --CR(25)R(26)R(27); H.sub.2b --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or Br, I, CN, --(Xa).sub.dg --C.sub.da H.sub.2da+1, --(Xb).sub.dh --(CH.sub.2).sub.db --C.sub.de F.sub.2de+1, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.df H.sub.2df R(.sup.30); where the aromatics phenyl, biphenylyl or naphthyl are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(31)R(32); -C.sub.4)-perfluoroalkyl; or --(Xe)--(CH.sub.2).sub.eb R(45); -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl or (CH.sub.2).sub.e --R(42); is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(43)R(44); -C.sub.4)-alkyl; or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; .ltoreq.eb is zero, 1, 2, 3 or 4; is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, NR(50)R(51) and --(Xfa)--(CH.sub.2).sub.ed --(Xfb)R(46); (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl;

where R(3) and R(4), however, cannot be hydrogen, and their pharmaceutically tolerable salts;

(HOE 94/F 265 - NZ 272 946, EP-A 700 904) ##STR38## in which: one of the three substituents R(1), R(2) and R(3) is (C.sub.1 -C.sub.9)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --NR(10)R(11) or --CR(10)R(11)R(12); is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl;

and the other substituents R(1), R(2) and R(3) in each case independently of one another are (C.sub.1 -C.sub.8)-alkyl, (C.sub.2 -C.sub.8)-alkenyl or --C.sub.m H.sub.2m R(14); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(15)R(1 6), one another are hydrogen, F, Cl, Br, I, --C.tbd.N, X--(CH.sub.2 .sub.p --(C.sub.q F.sub.2q+1), R(22)--SO.sub.u, R(23)R(24)N--CO, R(25)--CO-- or R(26)R(27)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched; (C.sub.2 -C.sub.6)-alkenyl, --C.sub.n H.sub.2n --R(29) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(30)R(31); -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or one another are OR(35) or NR(35)R(36); -C.sub.6)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, -C.sub.4)-alkyl, F, Cl, --OR(32), --NR(33)R(34) or C.sub.r F.sub.2r+1 ; (C.sub.1 -C.sub.3)-alkyl;

and their pharmaceutically tolerable salts;

(HOE 94/F 266 - EP-A 702 001, NZ 272 948) ##STR39## in which R(1) is hydrogen, F, Cl, Br, I, CN, NO.sub.2, OH, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ; (C.sub.3 -C.sub.6)-alkenyl, CF.sub.3 or --C.sub.n H.sub.2n --R(8); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-alkyl; or CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, or -C.sub.9)-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; latter linked via C or N, which are unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; --CF.sub.3)][R(15)], --C[(CF.sub.2).sub.r --CF.sub.3 ].dbd.CR(15)R(16); -C.sub.4)-alkyl; --(CH.sub.2).sub.s --(CF.sub.2).sub.t --CF.sub.3 ;

and their pharmaceutically tolerable salts;

(HOE 94/F 267 - EP-A 700 899, NZ 272 947) ##STR40## in which: one of the three substituents R(1), R(2) and R(3) is --Y--4-[(CH.sub.2).sub.k --CHR(7)--(C.dbd.O)R(8)]-phenylen, --Y--3- (CH.sub.2).sub.k --CH R(7)--(C.dbd.O)R(8)]-phenylen or --Y--2-[(CH.sub.2).sub.k --CHR(7)--(C.dbd.O)R(8)]-phenylen, where the phenyl in each case is unsubstituted or substituted by 1-2 substituents from the group F, Cl, --CF.sub.3, methyl, hydroxyl, methoxy, or --NR(37)R(38); -C.sub.8)-alkyl, --(C.sub.1 -C.sub.8)-alkanoyl, --(C.sub.1 -C.sub.8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl; or -C.sub.8)-alkyl or benzyl;

and the other radicals R(1), R(2) and R(3) in each case independently of one another are -(C.sub.1 -C.sub.8)-alkyl, -(C.sub.2 --C.sub.8)-alkenyl or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); another are R(18)R(19)N--(C.dbd.Y')--NH--SO.sub.2 --; -C.sub.8)-alkyl, --(C.sub.3 --C6)-alkenyl or --(CH.sub.2).sub.t --R(21); or substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methoxy and --(C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N-benzyl; another are hydrogen, F, Cl, Br, I, --C.tbd.N, X--(CH.sub.2).sub.p --(C.sub.q F.sub.2q+1), R(22)--SO.sub.u --, R(23)R(24)N--CO--, R(25)--CO-- or R(26)R(27)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched; -C.sub.8)-alkyl, --(C.sub.3 -C.sub.6)-alkenyl, --(CH.sub.2).sub.n --R(29) or --CF.sub.3 ; substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(30)R(31); -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N-benzyl; or another are --OR(35) or --NR(35)R(36); -C.sub.6)-alkyl; or group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N-benzyl; -C.sub.4)-alkyl, F, Cl, --OR(32), --NR(33)R(34) or --C.sub.r F.sub.2r+1 ; --(C.sub.1 -C.sub.3)-alkyl;

and their pharmaceutically tolerable salts;

(HOE 94/F 352 - EP-A 713 684, NZ 280 517) ##STR41## in which: R(1) is R(6)--CO or R(7)R(8)N--CO; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(9), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(10)R(11), -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(12); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n R(I15); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); -C.sub.4)-perfluoroalkyl; or is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino; hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(24); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(29); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(30)R(31); -C.sub.4)-perfluoroalkyl; -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or (CH.sub.2).sub.b C.sub.d F.sub.2d+1 or --C.sub.n H.sub.2n --R(36); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(37)R(38); -C.sub.4)-perfluoroalkyl; -C.sub.4)-perfluoroalkyl; group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; benzoylguanidine parent structure; or --CR(42)R(43)OH, --C.tbd.CR(45), --CR(46).dbd.CR(45) or --[CR(47)R(48)].sub.u --CO--[C(R49)R(50)].sub.v --R(44); --(CHOH).sub.q --(CH.sub.2).sub.r --(CHOH).sub.t --R(51) or --(CH.sub.2).sub.p --O--(CH.sub.2 --CH.sub.2 O).sub.q --R(51); -C.sub.6)-alkyl; or -C.sub.8)-cycloalkyl; --C.sub.e H.sub.2e --R(45); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53); substituted as phenyl; or 1-3 OH; hydrogen or methyl; or -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.f H.sub.2f --R(59); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; R(2), but where at least one of the substituents R(2), R(3), R(4) and R(5) must be OH;

and their pharmaceutically tolerable salts;

(HOE 95/F 007 K - EP-A 723 956, NZ 280 887) ##STR42## in which: one of the three substituents R(1), R(2) and R(3) is R(6)--A--B--D--; amidino group R(7)R(8)N--C[.dbd.N--R(9)]-- or a guanidino group ##STR43## R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or replaced by a heteroatom group O, SO.sub.m or NR(11), or H.sub.2a ; C.sub.a H.sub.2 a can be replaced by a heteroatom group O, SO.sub.m or NR(11); one or two methylene groups can be replaced by one of the groupings selected from the group consisting of --O--, --CO--, --CH[OR(20)]--, --SO.sub.m --, --NR(20)--, --NR(20)--CO--, --NR(20)--CO--NH--, --NR(20)--CO--NH--SO.sub.2 -- ##STR44## and --SO.sub.aa [NR(19)].sub.bb --; and where in the group C.sub.b H.sub.2b a methylene group can be replaced by --CH--R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring; ##STR45## R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF.sub.3 or --SO.sub.w --R(14); 1, 2, 3 or 4 carbon atoms;

and the other substituents R(1) and R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, --CN, --(C.sub.1 -C.sub.8)-alkyl, --(C.sub.2 -C.sub.8)-alkenyl, --NR(35)R(36) or R(.sup.17)--C.sub.g H.sub.2g --Z.sub.h --; 1, 2, 3, 4, 5 or 6 carbon atoms; or group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl; --NR(18)--CO--NH-- or --NR(18)--SO.sub.2 --; F.sub.2k+1 --; or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl and methoxy; or substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, hydroxyl, methoxy, --NR(37)R(38), CH.sub.3 SO.sub.2 -- and H.sub.2 NO.sub.2 S--; 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or --C.sub.r F.sub.2r+1 ; having 1, 2 or 3 carbon atoms;

and their pharmacologically tolerable salts;

(HOE 95/F 072 - EP-A 738 712, NZ 286 380) ##STR46## in which R(1) and R(2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, O-alkyl having 1, 2, 3 or 4 carbon atoms, O--C(.dbd.O)-- alkyl having 1, 2, 3 or 4 carbon atoms or C.sub.m H.sub.2m --NR(12)R(13); 1, 2, 3 or 4 carbon atoms; atoms, C(.dbd.O)-NH.sub.2, C(.dbd.O)--NH-alkyl having 1, 2, 3 or 4 carbon atoms, C(.dbd.O)-N(alkyl).sub.2 having 1, 2, 3 or 4 carbon atoms in each alkyl group, alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkynyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, alkenylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkenyl group, alkynylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkynyl group, C.sub.1 -C.sub.4 -alkyl-substituted aryl, C.sub.1 -C.sub.4 -alkylheteroaryl, C.sub.1 -C.sub.4 -alkenylheteroaryl, aminoalkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, substituted aryl, heteroaryl and substituted heteroaryl; having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, O-alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, halogen, (such as F, Cl, Br, I), OH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, O-lower alkyl, O-aryl, O-lower alkylaryl, O-substituted aryl, O-lower alkyl-substituted aryl, O--C(.dbd.O)--C.sub.1 -C.sub.4 -alkylaryl, O--C(.dbd.O)--NH--C.sub.1 -C.sub.4 -alkyl, O--C(.dbd.O)--N(C.sub.1 -C.sub.4 -alkyl).sub.2, NO.sub.2, CN, CF.sub.3, NH.sub.2, NH--C(.dbd.O)--C.sub.1 -C.sub.4 -alkyl, NH--C(.dbd.O)--NH.sub.2, COOH, C(.dbd.O)--O--C.sub.1 -C.sub.4 -alkyl, C(.dbd.O)--NH.sub.2, C(.dbd.O)-- NH--C.sub.1 -C.sub.4 -alkyl, C(.dbd.O)-N(C.sub.1 -C.sub.4 -alkyl).sub.2, C.sub.1 -C.sub.4 --COOH, C.sub.1 -C.sub.4 -alkyl-C(.dbd.O)--O--C.sub.1 -C.sub.4 -alkyl, SO.sub.3 H, SO.sub.2 -alkyl, SO.sub.2 -alkylaryl, SO.sub.2 --N--(alkyl).sub.2, SO.sub.2 -N(alkyl)(alkylaryl), C(.dbd.O)--R(11), C.sub.1 -C.sub.10 -alkyl--C(.dbd.O)--R(11), C.sub.2 -C.sub.10 -alkenyl--C(.dbd.O)-R(11), C.sub.2 -C.sub.10 -alkynyl--C(.dbd.O)--R(11), NH--C(.dbd.O)--C.sub.1 -C.sub.10 -alkyl--C(.dbd.O)--R(11), O--C.sub.1 -C.sub.11 -alkyl--C(.dbd.O)--R(11); substituted aryl, NH.sub.2, NH--C.sub.1 -C.sub.4 -alkyl, N--(C.sub.1 -C.sub.4 -alkyl).sub.2, SO.sub.3 H, SO.sub.2 -alkyl, SO.sub.2 -alkylaryl, SO.sub.2 --N-- (alkyl).sub.2, SO.sub.2 -N(alkyl)(alkylaryl); alkyl, cycloalkyl, aryl, alkylaryl; or ring;

(HOE 95/F 109 - EP 748 795, NZ 286 583) ##STR47## in which: R(1), R(2) and R(3) independently of one another are --Y--[4--R(8)-phenyl], --Y--[3--R(8)-phenyl] or --Y--[2--R(8)-phenyl], where the phenyl is in each case unsubstituted or substituted by 1-2 substituents from the group consisting of F, Cl, --CF.sub.3, methyl, hydroxyl, methoxy and --NR(96)R(97); --(C.sub.1 -C.sub.8)-alkyl, benzyl, --(C.sub.2 -C.sub.8)-alkylene-NR(11)R(12), (C.sub.2 -C.sub.8)-alkylene-NR(13)--(C.sub.2 -C.sub.8)-alkylene-NR(37)R(38) or (C.sub.0 -C.sub.8)-alkylene--CR(39)R(40)CR(41 )R(42)(C.sub.0 -C.sub.8)-alkylene-NR(43)R(44); another are hydrogen, --(C.sub.1 -C.sub.8)-alkyl or benzyl; --(C.sub.1 -C.sub.8)-alkyl or --(C.sub.0 -C.sub.3)-alkylenephenyl, where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl and methoxy; or group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N--benzyl; or alkyl having 1, 2, 3 or 4 carbon atoms; or pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl, methoxy; or -C.sub.8)-alkyl, --(C.sub.2 -C.sub.8)-alkenyl or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); --Q--4-[(CH.sub.2).sub.k --CHR(17)--(C.dbd.O)R(20)]-phenylen, --Q--3--(CH.sub.2).sub.k --CHR(17)--(C.dbd.O)R(20)]-phenylen or --Q--2-[(CH.sub.2).sub.k --CHR(17)--(C.dbd.O)R(20)1-phenylen, where the phenyl in each case is unsubstituted or substituted by 1-2 substituents from the group F, Cl, --CF.sub.3, methyl, hydroxyl, methoxy and --NR(35)R(36); -C.sub.8)-alkyl, --(C.sub.1 -C.sub.8)-alkanoyl, --(C.sub.1 -C.sub.8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl; or -C.sub.8)-alkyl or benzyl; -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents from the group F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --CR(25)R(26)R(27); unsubstituted or substituted by 1-3 substituents from the group F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl, or -C.sub.9)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --NR(28)R(29) or --CR(28)R(29)R(30); is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; (C.sub.1 -C.sub.4)-alkyl; or I, --C.tbd.N, T--(CH.sub.2).sub.h --(C.sub.i F.sub.2i+1), R(31)SO.sub.l --, R(32)R(33)N--CO--, R(34)--CO-- or R(45)R(46)N--SO.sub.2, where the perfluoroalkyl group is straight-chain or branched; -C.sub.8)-alkyl, --(C.sub.3 -C.sub.6)-alkenyl, (CH.sub.2).sub.n R(48) or --CF.sub.3 ; substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(49)R(50); 1, 2, 3 or 4 carbon atoms; or of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl; or an amidino group R(52)R(53)N--C[.dbd.N--R(54)]-or a guanidino group R(52)R(53)N--C[.dbd.N--R(54)]--NR(55)--; alkyl having 1, 2, 3 or 4 carbon atoms; or H.sub.2.alpha.  can be replaced by a heteroatom group O, SO.sub.d or NR(56), or C.sub..gamma. H.sub.2.gamma. ; H.sub.2.gamma.  can be replaced by a heteroatom group O, SO.sub.d or NR(56); H.sub.2e a carbon atom can be replaced by one of the groupings --O--, --CO--, --CH[OR(57)]--, --SO.sub.r --, --NR(57)--, --NR(57)--CO--, --NR(57)--CO--NH--, --NR(57)--CO--NH-- SO.sub.2 -- or --NR(57)--SO.sub.2 --; ##STR48## R(58) and R(59) independently of one another are hydrogen, methyl, methoxy, F, Cl, Br, I, CF.sub.3 or--SO.sub.s --R(60); 1, 2, 3 or 4 carbon atoms; --CF[R(65)][R(66)], --CF[(CF.sub.2).sub.q --CF.sub.3)][R(65)], --C[(CF.sub.2).sub.p --CF.sub.3 ].dbd.CR(65)R(66); 5, 6 or 7 carbon atoms; 1, 2, 3 or 4 carbon atoms; --NR(67)R(68); 1, 2, 3, 4, 5 or 6 carbon atoms; or CH.sub.2 group can be replaced by oxygen, --S--, SO.sub.2, --NH--, --NCH.sub.3 or --N-benzyl; 3 or 4 carbon atoms, F, Cl, --OR(69), --NR(70)R(71) or --C.sub.z F.sub.2z+1 ; having 1, 2 or 3 carbon atoms; 2, 3 or 4 carbon atoms;

and their pharmaceutically tolerable salts;

(HOE 95/F 115 - EP 744 397, NZ 286 622) formula I ##STR49## in which: R(6) is hydrogen, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or phenyl, where the phenyl group is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoroalkyl; or F; where, however, at least one of the radicals R(1), R(2), R(3), R(4) and R(5) must be fluorine;

and their pharmaceutically tolerable salts; ##STR50## in which: R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5 or 6 carbon atoms, CF.sub.3 or --C.sub.n H.sub.2n --R(7); is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, --C.sub.s H.sub.2s --(C.sub.3 -C.sub.8)-cycloalkyl or an aromatic system selected from the group consisting of pyridyl, pyrrolyl, quinolyl, isoquinolyl, imidazolyl or phenyl; isoquinolyl, imidazolyl and phenyl are unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

and their pharmaceutically tolerable salts;

(HOE 95/F 173 - NZ 299 052) ##STR51## in which: at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is --X.sub.a --Y.sub.b --L.sub.n --U; 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group; is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(21)R(22); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; 8 or 9 carbon atoms; 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, I, CN, --O.sub.n --C.sub.m H.sub.2m+1, --O.sub.p --(CH.sub.2).sub.s --C.sub.q F.sub.2q+1 or C.sub.r H.sub.2r R(10); where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(11)R(12); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

and their pharmaceutically tolerable salts;

(HOE 95/F 220 - NZ 299 052) ##STR52## in which: at least one of the substituents R(1), R(2) and R(3) is R(6)--C(OH).sub.2 --; straight-chain or branched;

and the other substituents R(1), R(2) and R(3) independently of one another are hydrogen, OH, F, Cl, Br, I, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, or phenoxy, which is unsubstituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, methyl and methoxy; or alkyl--SO.sub.x, --CR(7).dbd.CR(8)R(9) or --C.dbd.--CR(9); 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, the group consisting of F, Cl, CF.sub.3, methyl and methoxy; or phenyl, C.sub.6 H.sub.5 --(C.sub.1 -C.sub.4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl or imidazolyl, where quinolinyl, isoquinolinyl or imidazolyl are bonded via C or N and where phenyl, C.sub.6 H.sub.5 --(C.sub.1 -C.sub.4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl and imidazolyl are unsubstituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or SR(10), --OR(10), --CR(10)R(11)R(12); isoquinolinyl, pyridinyl, imidazolyl or phenyl, where the aromatic systems quinolinyl, isoquinolinyl, pyridinyl, imidazolyl and phenyl are unsubstituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or alkyl having 1, 2, 3 or 4 carbon atoms; or 3 carbon atoms, F, Cl, Br, I, CN, OR(13), NR(14)R(15), --(CH.sub.2)n--(CF.sub.2).sub.o --CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms;

and their pharmacologically acceptable salts;

(HOE 95/F 253 - NZ 299 682) ##STR53## in which: at least one of the three substituents R(1), R(2) and R(3) is a benzoylguanidine, ##STR54## which is unsubstituted or substituted in the phenyl moiety by 1-4 radicals selected from the group consisting of alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, --(CH.sub.2).sub.m --R(14), F, Cl, Br, I, --C.tbd.N, CF.sub.3, R(22)SO.sub.2 --, R(23)R(24)N--CO--, R(25)--CO--, R(26)R(27) N--SO.sub.2, --OR(35), --SR(35) or --N R(35)R(36); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH.sub.2).sub.n R(29) or --CF.sub.3 ; substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(30)R(31);

or

R(23), R(25) and R(26) are hydrogen;

R(24) and R(27) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(23) and R(24), and also R(26) and R(27) together are 5 or 6 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl;

R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

or

R(35) and R(36) together are 4-7 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl;

or

R(35) is phenyl, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy, SO.sub.2 R(5), SO.sub.2 NR(6)R(7) and --NR(32)R(33); 2, 3 or 4 carbon atoms; 1, 2, 3 or 4 carbon atoms;

or

R(35) is C.sub.1 -C.sub.1 -heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

and the other substituents R(1), R(2) and R(3) in each case independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH.sub.2).sub.p R(10); substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy, --SO.sub.2 NR(17)R(8) and --SO.sub.2 R(9); 2, 3 or 4 carbon atoms;

or

the other radical R(1) or R(3) in each case is hydrogen,

R(4) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; and their pharmaceutically tolerable salts; (HOE 95/F 265 - NZ 299 739) ap) benzoylguanidines of the formula I ##STR55## in which:

R(1) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or NR(7)R(8); 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

R(2) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --SO.sub.2 R(9);

R(3) is hydrogen, --SR(25), --OR(25), --NR(25)R(26) or --CR(25)R(26)R(27); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

or

R(25) by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

(4) is hydrogen, F, Cl, Br, I, OH, --C.tbd.N, CF.sub.3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14);

m is zero, 1 or 2; substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16);

R(5) and R(6) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms;

and their pharmaceutically tolerable salts; (HOE 95/F 269 K- EP 774 458) aq) benzenedicarboxylic acid diguanidides of the formula I ##STR56## in which: one of the radicals R(1), R(2), R(3) and R(4) is --CO--N.dbd.C(NH.sub.2).sub.2 ;

and of the other radicals R(1), R(2), R(3) and R(4) in each case:

R(1) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms;

R(2) and R(4) independently of one another are hydrogen, F, Cl, Br, I, OH, --CN, CF.sub.3, --CO--N.dbd.C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14);

m is zero, 1 or 2;

R(14) is --(C.sub.3 -C.sub.8)-cycloalkyl or phenyl, from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16);

or

R(2) and R(4) independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl, methoxy;

or

R(2) and R(4) independently of one another are R(22)-SO.sub.2 --, R(23)R(24)N--CO--, R(28)--CO-- or R(29)R(30)N--SO.sub.2 ;

R(22) and R(28) independently of one another are methyl or --CF.sub.3 ;

R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;

or

R(2) and R(4) independently of one another are --OR(35) or --NR(35)R(36); 1, 2, 3, 4, 5 or 6 carbon atoms;

or

R(35) and R(36) together are 4-7 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl;

R(3) is hydrogen, --SR(25), --OR(25), --NR(25)R(26), --CR(25)R(26)R(27);

R(25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

or

R(25) is --(C.sub.1 -C.sub.9)-heteroaryl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

R(5) is alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, X--(CH.sub.2).sub.y --CF.sub.3 or phenyl,

which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(6)R(7);

X is a bond or oxygen;

y is zero, 1 or 2;

their pharmaceutically tolerable salts; (HOE 95/F 269 BK - EP 774 457) ar) benzenedicarboxylic acid diguanidides of the formula I ##STR57## in which:

one of the radicals R(1), R(2), R(3) and R(5) is --CO--N.dbd.C(NH.sub.2).sub.2 ;

and of the other radicals R(1), R(2), R(3) and R(5) in each case:

R(1) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or4 carbon atoms;

R(2) is hydrogen, F, Cl, Br, I, OH, --CN, CF.sub.3, --CO--N.dbd.C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14);

m is zero, 1 or 2; substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16);

or

R(2) is R(22)--SO.sub.2 --, R(23)R(24)N--CO--, R(28)--CO-- or R(29)R(30)N--SO.sub.2 ;

R(22) and R(28) independently of one another are methyl or --CF.sub.3 ;

R(23), R(24), R(29) and R(30) independently of one another are hydrogen or methyl;

or

R(2) is --OR(35) or --NR(35)R(36);

R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or6 carbon atoms;

or

R(35) and R(36) together are 4-7 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or-N-benzyl;

R(3) is hydrogen, --SR(25), --OR(25), --NR(25)R(26), --CR(25)R(26)R(27); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

or

R(25) is --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(26) and R(27) independently of one another are defined as R(25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

R(4) is CF.sub.3, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, --(C.sub.3 -C.sub.8)-cycloalkyl or --(CH.sub.2).sub.m R(14);

m is 1 or 2;

R(14) is --(C.sub.3 -C.sub.8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16);

or

R(4) is phenyl, which is substituted by 2, 3, 4 or five substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and --NR(1 5)R(16);

and their pharmaceutically tolerable salts; (HOE 96/F 013 - EP-A 787 717) as) diaryldicarboxylic acid diguanidides of the formula I ##STR58## in which: one of the radicals R(1), R(2), R(3), R(4) and R(5) is --CO--N.dbd.C(NH.sub.2).sub.2 ;

the other radicals R(1) and R(5) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms;

the other radicals R(2) and R(4) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, --CN, CF.sub.3, --CO--N.dbd.C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14);

m is zero, 1 or 2;

R(14) is --(C.sub.3 -C.sub.8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16);

or

the other radicals R(2) and R(4) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl, methoxy;

or

the other radicals R(2) and R(4) in each case are R(22)--SO.sub.2 --, R(23)R(24)N--CO--, R(28)--CO-- or R(29)R(30)N--SO.sub.2 ; methyl;

or

the other radicals R(2) and R(4) in each case independently of one another are --OR(35) or --NR(35)R(36); 1, 2, 3, 4, 5 or 6 carbon atoms;

or

R(35) and R(36) together are 4-7 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl;

the other radical R(3) in each case is hydrogen, --SR(25), --OR(25), --NR(25)R(26), --CR(25)R(26)R(27); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

one of the radicals R(6), R(7), R(8), R(9) and R(10) is --CO--N.dbd.C(NH.sub.2).sub.2 ;

the other radicals R(6) and R(10) in each case independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(132), --NR(133)R(134) or CF.sub.3 ; alkyl having 1, 2, 3 or 4 carbon atoms;

the other radicals R(7) and R(9) in each case independently of one another are hydrogen, F, Cl, Br, I, OH, --CN, CF.sub.3, --CO--N.dbd.C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.mm R(1 14);

mm is zero, 1 or 2;

R(114) is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(115)R(116);

or

the other radicals R(7) and R(9) in each case independently of one another are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl and methoxy;

or

the other radicals R(7) and R(9) in each case are R(122)--SO.sub.2 --, R(123)R(124)N--CO--, R(128)--CO-- or R(129)R(130)N--SO.sub.2 ; or methyl;

or

the other radicals R(7) and R(9) in each case independently of one another are --OR(135) or --NR(135)R(136); 1, 2, 3, 4, 5 or 6 carbon atoms;

or

R(135) and R(136) together are 4-7 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl;

the other radical R(8) in each case is hydrogen, --SR(125), --OR(125), --NR(125)R(126) or --CR(125)R(126)R(127); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

or

R(1 25)

is --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(126) and R(127) independently of one another are defined as R(125) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

A is absent or is --NR(11)--CO--, --NR(12)--CO--NR(13)--, --NR(17)--CO--NR(18)--SO.sub.2 --, --NR(19)--SO.sub.2 --, --SO.sub.2 --NR(19)--SO.sub.2 --, --SO.sub.2 --NR(19)--CO--, --O--CO--NR(19)--SO.sub.2 -- or --CR(20).dbd.CR(21)--;

R(11), R(12), R(13), R(17), R(18), R(19), R(20) and R(21) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms

and their pharmaceutically tolerable salts; (HOE 96/F 026 - EP 790 245) at) substituted thiophenylalkenylcarboxylic acid guanidides of the formula I ##STR59## in which:

at least one of the substituents R(1), R(2) and R(3) is --O.sub.p --(CH.sub.2).sub.s -C.sub.q F.sub.2q+1, R(40)CO-- or R(31)SO.sub.k --;

p is zero or 1;

s is zero, 1, 2, 3 or 4;

q is 1, 2, 3, 4, 5, 6, 7 or 8;

k is zero, 1 or 2; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl and methoxy; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl or methoxy;

or

R(31) is NR(41)R(42); 2, 3 or 4 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms,

or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

and the other substituents R(1), R(2) and R(3) in each case independently of one another are H, F, Cl, Br, I, CN, --O.sub.na -C.sub.ma H.sub.2ma+1 or --O.sub.ga C.sub.ra H.sub.2ra R(10);

na is zero or 1;

ma is zero, 1, 2, 3, 4, 5, 6, 7 or 8;

ga is zero or 1;

ra is zero, 1, 2, 3 or 4;

R(1 0) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl and methoxy;

R(4) and R(5) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

and their pharmaceutically tolerable salts; (HOE 96/F 032 - EP 791 577) au) ortho-substituted benzoylguanidines of the formula I ##STR60## in which:

R(2) and R(3) independently of one another are hydrogen, Cl, Br, I, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or --OR(5); -C.sub.8)-cycloalkyl; d is zero, 1 or 2;

where one of the two substituents R(2) and R(3) is always hydrogen but both substituents R(2) and R(3) are not simultaneously hydrogen, and their pharmaceutically tolerable salts; (HOE 96/F 042 - EP 794 171) av) benzoylguanidines of the formula I ##STR61## in which:

R(1) is H, F, Cl, Br, I, CN, NO.sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ;

x is oxygen, S, NR(5),

a is zero or 1;

b is zero, 1 or 2;

c is zero, 1, 2 or 3; R(6); biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); atoms;

or

R(1) is --SR(10), --OR(10) or --CR(10)R(11)R(12);

R(10) is --C.sub.f H.sub.2 f-cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms in the cycloalkyl ring, or phenyl, from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(11) and R(12) independently of one another are defined as R(10) or are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(1) is phenyl, naphthyl, biphenylyl or heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino,

or

R(1) is --SR(13), --OR(13), --NHR(13), --NR(13)R(14), --CHR(13)R(15), --C[R(15)R(16)OH], --C.tbd.CR(18), --C[R(19)].dbd.CHR(18), --C[R(20)R(2 1 )].sub.k -(CO)--[CR(22)R(23)].sub.I -R(24),

k is zero, 1, 2, 3 or 4;

I is zero, 1, 2, 3 or 4; -(CHOH).sub.h -(CH.sub.2).sub.i - (CHOH).sub.j -R(17) or --(CH.sub.2).sub.g --O--(CH.sub.2 -CH.sub.2 O).sub.h -R(24); R(17) is hydrogen or methyl, g, h and i

R(15) and R(16) identically or differently are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R(18) selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); R(25) and R(26)

or

R(18) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or substituted as phenyl;

or

R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or substituted by 1-3 OH;

or

R(1 8) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R(19), R(20), R(21), R(22) and R(23) identically or differently are hydrogen or methyl;

R(24) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.m H.sub.2 m-R(18);

m is 1, 2, 3 or 4;

R(2) and R(3) are defined as R(1);

R(4) is alkyl having 1, 2, 3 or 4 carbon atoms; and their pharmaceutically tolerable salts; (HOE 96/F 043 - EP 794 172) aw) ortho-substituted benzoylguanidines of the formula I ##STR62## in which:

R(1) is H, F, Cl, Br, I, CN, NO.sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ;

X is oxygen, S, NR(5),

a is zero or 1;

b is zero, 1 or 2;

c is zero, 1, 2 or 3; R(.sup.6); biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); atoms;

or

R(1) is --SR(10), --OR(10) or --CR(10)R(11)R(12);

R(10) is --C.sub.f H.sub.2f -cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms in the cycloalkyl ring, or phenyl, from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

f is zero, 1 or 2;

R(11) and R(12) independently of one another are defined as R(10), or are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(1) is phenyl, naphthyl, biphenylyl or heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino,

or

R(1) is --SR(13), --OR(13), --NHR(13), --NR(13)R(14), --CHR(13)R(15), --C[R(15)R(16)OH], --C.tbd.CR(18), --C[R(19)].dbd.CHR(18), --C[R(20)R(2 1 )].sub.k --(CO)--[CR(22)R(23)].sub.I --R(24), --(CHOH).sub.h --(CH.sub.2).sub.i --(CHOH).sub.j --R(17) or --(CH.sub.2).sub.g --O--(CH.sub.2 --CH.sub.2 O).sub.h --R(24);

R(15) and R(16) identically or differently are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R(18) is phenyl, group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26);

or

R(1 8) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or substituted as phenyl;

or

R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or substituted by 1-3 OH;

or

R(18) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R(19), R(20), R(21), R(22) and R(23) identically or differently are hydrogen or methyl;

R(24) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.m H.sub.2m --R(18);

m is 1, 2, 3 or 4;

one of the two substituents R(2) and R(3) is hydroxyl;

and

the other of the substituents R(2) and R(3) in each case is defined as R(1);

R(4) is alkyl having 1, 2, 3 or 4 carbon atoms; alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I or --(CH.sub.2).sub.n --(CF.sub.2).sub.O --CF.sub.3 ;

n is zero or 1;

o is zero or 1;

and their pharmaceutically tolerable salts; (HOE 96/F 135 - EP 810 207) ax) bis-ortho-substituted benzoylguanidines of the formula I ##STR63## in which:

R(2) and R(3) independently of one another are R(10)--SOR.sub.a -- or R(14)R(15)N--SO.sub.2 --;

a is zero, 1 or 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5 or 6 carbon atoms or --C.sub.ab H.sub.2ab --R(16);

ab is zero, 1, 2, 3 or 4; from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(17)R(18); alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(14) and R(15) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl;

or

or

R(1), R(2) and R(3) independently of one another are SR(21), --OR(22), --NR(23)R(24) or --CR(25)R(26)R(27); H.sub.2b --(C.sub.1 -C.sub.9)-heteroaryl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

b is zero, 1 or 2;

R(24), R(26) and R(27) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or

R(1), R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, I, CN, --(Xa).sub.dg --C.sub.da H.sub.2da+1, --(Xb).sub.dh --(CH.sub.2).sub.db --C.sub.de F.sub.2de+1, alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.df H.sub.2df R(.sup.30);

(Xa) is oxygen, sulfur or NR(33);

R(33) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

dg is zero or 1;

(Xb) is oxygen, sulfur or NR(34); having 1, 2, 3 or 4 carbon atoms;

dh is zero or 1;

da is zero, 1, 2, 3, 4, 5, 6, 7 or 8;

db is zero, 1, 2, 3 or 4;

de is zero, 1, 2, 3, 4, 5, 6 or 7;

df is zero, 1, 2, 3 or 4;

R(30) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(31)R(32); perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or

R(1), R(2) and R(3) independently of one another are NR(40)R(41) or --(Xe)--(CH.sub.2).sub.eb R(45);

R(40) and R(41) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or (CH.sub.2).sub.e --R(42);

e is zero, 1, 2, 3 or 4;

R(42) is cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(43)R(44); alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(40) and R(41) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl;

(Xe) is oxygen, sulfur or NR(47); having 1, 2, 3 or 4 carbon atoms;

eb is zero, 1, 2, 3 or 4;

R(45) is cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, or phenyl, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, --(Xfb)R(46); alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3 or 4 carbon atoms;

or

R(1), R(2) and R(3) independently of one another are --CHR(52)R(53); --R(54) or --(CH.sub.2).sub.g --O--(CH.sub.2 --CH.sub.2 O).sub.h --R(54);

R(53) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(1), R(2) and R(3) independently of one another are --C(OH)R(55)R(56); 2, 3 or 4 carbon atoms;

or

R(55) and R(56) together are cycloalkyl having 3, 4, 5 or 6 carbon atoms;

or

R(55) is --CH.sub.2 OH;

and

(4) and R(5) independently of one another are alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, OH, F, Cl, Br, I, CN, --O.sub.n --(CH.sub.2).sub.O --(CF.sub.2).sub.p --CF.sub.3 ;

n is zero or 1;

o is zero, 1 or 2;

p is zero, 1 or 2;

and their pharmaceutically tolerable salts; (96/F 136 - EP 810 205) ay) substituted 1-naphthoylguanidines of the formula I ##STR64## in which:

R2,R3,R4,R5,R6,R7and R8 independently of one another are H, F, Cl, Br, I, CN, NO.sub.2, CF.sub.3, C.sub.2 F.sub.5 or X.sub.a Y.sub.b Z; SO.sub.2, SO.sub.2 NR(10), OC.dbd.O, NR(10)C.dbd.O or NR(10)SO.sub.2, the left atom;

R(10), R(11) and R(12) independently of one another are H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;

a is zero or 1;

Y is alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 CH.sub.2 groups, where one of these CH.sub.2 groups can be replaced by O, S, NR(13) or o-, p- or m-phenylene; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms;

b is zero or 1;

Z is H, alkyl having 1, 2, 3, 4, 5, 6 or 7 carbon atoms, cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms, C(.dbd.O)R(15), SO.sub.2 R(15), NR(16)R(17) or phenyl, from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(21)R(22); or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; NR(18)R(19) or OR (20); 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or

R(18) and R(19) together are 4 or 5 methylene groups, N-benzyl or N-(p-chlorophenyl);

R(20) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;

R(16) and R(17) independently of one another are H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or

R(16) and R(17) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3, N-benzyl or N-(p-chlorophenyl);

or

Z is an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(21)R(22);

but where, in the case where R(4) is an alkoxy radical, at least one of the substituents R(2), R(3), R(5), R(6), R(7) and R(8) is not hydrogen; and their pharmaceutically tolerable salts; (96/F 137 - EP 810 206) az) substituted 2-naphthoylguanidines of the formula I ##STR65## in which:

at least one of the substituents RI, R3, R4, R5, R6, R7 and R8 is XY.sub.a WZ or X'Y.sub.a WZ'; 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; these CH.sub.2 groups can be replaced by O, S, NR(13) or o-, p- or m-phenylene; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; follow a heteroatom of the group XY.sub.a --alternatively O or NR(14); having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; NR(14)--alternatively NR(16)R(17); NR(18)R(19) or OR(20); 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or N-benzyl or N-(p-chlorophenyl); having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;

R(16) and R(17) independently of one another are H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or,

R(16) and R(17) together are 4 or 5 methylene groups, N-benzyl or N-(p-chlorophenyl);

X' is C.dbd.O, C(.dbd.O)NR(30), C(.dbd.O)O, SO, SO.sub.2, SO.sub.2 NR(30), OC.dbd.O, ring in each case takes place via the left atom; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms;

Z' is C(.dbd.O)R(15), SO.sub.2 R(15), an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(21)R(22); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; or OR(20); 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or N-benzyl or N-(p-chlorophenyl); having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbor atoms;

or

Z'--if W is not O or NR(14)--is NR(16)R(17); R(16) and R(17) independently of one another are H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or

R(16) and R(17) together are 4 or 5 methylene groups, N-benzyl or N-(p-chloro-phenyl);

and the other substituents R1, R3, R4, R5, R6, R7 and R8 in each case, which are still not allocated by the definitions given above, C.sub.2 F.sub.5 or V.sub.p Q.sub.q U; C(.dbd.O)O or CR(66)R(67); 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; these CH.sub.2 groups can be replaced by O, S, NR(68) or o-, p- or m-phenylene; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; 3, 4, 5, 6 or 7 carbon atoms, C(.dbd.O)R(65), SO.sub.2 R(65), NR(61)R(62) or phenyl, from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(63)R(64); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

R(65) is N.dbd.C(NH.sub.2).sub.2, NR(61)R(62) or OR(60); 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or N-benzyl or N-(p-chlorophenyl);

or

U is an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(63)R(64);

but where at least one of the substituents R5, R6, R7 and R8 is not hydrogen; and their pharmaceutically tolerable salts; (96/F 141 - EP 811 610) ba) ortho-substituted benzoylguanidines of the formula I ##STR66## in which:

(1) is H, F, Cl, Br, I, CN, NO.sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ;

x is oxygen, sulfur or NR(9);

a is zero or 1;

b is zero, 1 or 2;

c is zero, 1, 2 or 3; R(6); biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); atoms;

or

R(1) is --SR(10), --OR(10) or --CR(10)R(11)R(12); atoms in the cycloalkyl ring, heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms or phenyl, substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino;

R(11) and (R12), independently of each other, are defined as R(10) or are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(1) is phenyl, naphthyl, biphenylyl or heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8, or 9 carbon atoms, the latter linked via a carbon or nitrogen atom of the ring, selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethyl-amino,

or

(R1) is --SR(13), --OR(13), --NHR(13), --NR(13)R(14), --CHR(13)R(15), --C[R(15)R(16)OH], --C.tbd.CR(18), --C[R(19)].dbd.CHR(18), --C[R(20)R(21)].sub.k --(CO)--[CR(22)R(23)].sub.I --R(24), --(CHOH).sub.h --(CH.sub.2).sub.i --(CHOH).sub.kk -R(17) or --(CH.sub.2).sub.g --O--(CH.sub.2 --CH.sub.2 O).sub.h --R(24);

R(15) and R(16), identically or differently, are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, or, together with the carbon atom carrying them, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R(18) is phenyl, the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26);

or

R(18) is heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, which is unsubstituted or is substituted as phenyl;

or

R(18) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is unsubstituted or is substituted by 1-3 OH;

or

R(18) is cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms;

R(19), R(20), R(21), R(22) and R(23), identically or differently, are hydrogen or methyl;

R(24) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.m H.sub.2m --R(18);

one of the two substituents R(2) and R(3) is

--O--CO--R(27);

R(27) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl, naphthyl, pyridyl or quinolinyl, or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); 2, 3 or 4 carbon atoms;

where one of the substituents R(2) and R(3) is always defined as R(1);

R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, CN or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3,

n is zero or 1,

o is zero or 1,

and their pharmaceutically tolerable salts; (HOE 96/F 154 - EP 814 077) bb) benzoylguanidines of the formula I ##STR67## in which:

R(1) is R(13)--SO.sub.m or R (14)R(15)N--SO.sub.2 --; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.n H.sub.2n --R(16), biphenylyl or naphthyl, substituted by 1-3 substituents selected from the group consisting of F, Cf, CF.sub.3, methyl, methoxy and NR(25)R(26); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

R(14) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.n H.sub.2n --R(27), biphenylyl or naphthyl, substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

R(15) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

or

R(14) and R(15) are, together, 4 or 5 methylene groups of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

one of the substituents R(2) and R(3) is hydrogen;

and the other of the substituents R(2) and R(3) in each case is --CHR(30)R(31); --(CHOH).sub.k --R(32) or --(CH.sub.2).sub.g --O--(CH.sub.2 --CH.sub.2 O).sub.h --R(24);

or the other of the substituents R(2) and R(3) in each case is --C(OH)R(33)R(34);

R(31), R(33) and R(34) are, identically or differently, hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms,

or

R(33) and R(34) are, together, cycloalkyl having 3, 4, 5 or 6 carbon atoms;

or

R(33) is --CH.sub.2 OH;

R(4) is alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, CN or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ;

and their pharmaceutically tolerable salts; (HOE 96/F 202 - EP 837 055) bc) indanylidineacetylguanidines of the formula I ##STR68## in which:

R1, R2, R3, R4, R5 and R6 independently of one another are H, C.sub.1 -C.sub.10 -alkyl; haloalkyl having 1-6 carbon atoms, O--C.sub.1 -C.sub.10 -alkyl, haloalkoxy having 1-6 carbon atoms, F, Cl, Br, I, aryl, substituted aryl, heteroaryl, substituted heteroaryl, OH, O-lower alkyl, O-aryl, O-lower alkylaryl, O-substituted aryl, O-lower alkyl-substituted aryl, O--C(.dbd.O)--C.sub.1 -C.sub.4 -alkylaryl, O--C(.dbd.O)--NH--C.sub.1 -C.sub.4 -alkyl, O--C(.dbd.O)--N(C.sub.1 -C.sub.4 -alkyl).sub.2, NO.sub.2, CN, CF.sub.3, NH.sub.2, NH--C(.dbd.O)--C.sub.1 -C.sub.4 -alkyl, NH--C(.dbd.O)--NH.sub.2, COOH, C(.dbd.O)--O--C.sub.1 -C.sub.4 -alkyl, C(.dbd.O)--NH.sub.2, C(.dbd.O)--NH--C.sub.1 -C.sub.4 -alkyl, C(.dbd.O)--N(C.sub.1 -C.sub.4 -alkyl).sub.2, C.sub.1 -C.sub.4 --COOH, C.sub.1 -C.sub.4 -alkyl--C(.dbd.O)--O--C.sub.1 -C.sub.4 -alkyl, SO.sub.3 H, SO.sub.2 -alkyl; SO.sub.2 -alkylaryl, SO.sub.2 --N--(alkyl).sub.2, SO.sub.2 -N(alkyl)(alkylaryl), C(.dbd.O)--R11, C.sub.1 -C.sub.10 -alkyl-C(.dbd.O)--R11, C.sub.2 -C.sub.10 -alkenyl-C(.dbd.O)--R11, C.sub.2 -C.sub.10 -alkynyl-C(.dbd.O)--R11, NH--C(.dbd.O)--C.sub.1 -C.sub.10 -alkyl-C(.dbd.O)-R11 or O--C.sub.1 -C.sub.11 -alkyl-C(.dbd.O)--R11; substituted aryl, NH.sub.2, NH--C.sub.1 -C.sub.4 -alkyl, N--(C.sub.1 -C.sub.4 -alkyl).sub.2, SO.sub.3 H, SO.sub.2 -alkyl, SO.sub.2 -alkylaryl, SO.sub.2 -N-(alkyl).sub.2 or SO.sub.2 -N(alkyl)(alkylaryl);

x is O, S or NH;

R7, R8, R9 and R10 independently of one another are H, alkyl, cycloalkyl, aryl, alkylaryl,

or

R8 and R9 together are part of a 5-, 6- or 7-membered heterocyclic ring; or their pharmaceutically acceptable salts; (HOE 96/F 226 - EP 825 178) bd) phenyl-substituted alkenylcarboxylic acid guanidides of the formula I ##STR69## in which:

T is ##STR70##

R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C.sub.1 -C.sub.4)-alkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, (C.sub.3 -C.sub.8)-cycloalkyl oder NR(7)R(8)

r is zero or 1;

a is zero, 1, 2, 3 or 4;

b is 1, 2, 3 or 4;

R(6) is (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-perfluoroalkyl, (C.sub.3 -C.sub.6)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoro-alkyl;

or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl;

R(B), R(C) and R(D) independently are defined as R(A);

x is zero, 1 or 2;

y is zero, 1 or 2;

R(F) is hydrogen, F, Cl, Br, I, CN, OR(12), (C.sub.1 -C.sub.8)-alkyl, O.sub.p (CH.sub.2).sub.f C.sub.g F.sub.2g+1, (C.sub.3 -C.sub.8)-cycloalkyl or (C.sub.1 -C.sub.9)-heteroaryl;

p is zero or 1;

f is zero, 1, 2, 3 or 4;

g is 1, 2, 3, 4, 5, 6, 7 or 8;

R(12) is (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.4)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl;

R(E) is defined independently as R(F);

R(1) is defined independently as T;

or

R(1) is hydrogen, --O.sub.k C.sub.m H.sub.2m+1, --O.sub.n (CH.sub.2).sub.p C.sub.q F.sub.2q+1, F, Cl, Br, I, CN, --(C.dbd.O)-- N.dbd.C(N H.sub.2).sub.2, --SO.sub.r R(17), --SO.sub.r2 NR(31 )R(32), --O.sub.u (CH.sub.2).sub.v C.sub.6 H.sub.5, --O.sub.u2 --(C.sub.1 -C.sub.9)-heteroaryl or --S.sub.u2 -(C.sub.1 -C.sub.9)-heteroaryl;

k is zero or 1;

m is zero, 1, 2, 3, 4, 5, 6, 7 or 8;

n is zero or 1;

p is zero, 1, 2, 3 or 4;

q is 1, 2, 3, 4, 5, 6, 7 or 8;

r is zero, 1 or 2;

r2 is zero, 1 or 2;

R(31) and R(32) independently of one another are hydrogen, (C.sub.1 -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-perfluoroalkyl;

or

R(31) and R(32) are, together, 4 or 5 methylene groups of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

R(17) is (C.sub.1 -C.sub.8)-alkyl;

U is zero or 1;

u2 is zero or 1;

v is zero, 1, 2, 3 or 4; where the phenyl nucleus is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w NR(21)R(22), NR(18)R(19) and (C.sub.1 -C.sub.9)-heteroaryl; -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl;

w is 1, 2, 3 or 4;

where the heterocycle of the (C.sub.1 -C.sub.9)-heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl or methoxy;

R(2), R(3), R(4) and R(5) independently of one another are defined as R(1),

or

R(1) and R(2) or R(2) and R(3) in each case together are --CH--CH.dbd.CH--CH--, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w2 NR(24)R(25) and NR(26)R(27); -C.sub.4)-perfluoroalkyl;

w2 is 1, 2, 3 or 4;

the radical T being present in the molecule at least twice, but only three times at most;

and their pharmaceutically tolerable salts; (HOE 97/F 082) be) benzoylguanidines of the formula I ##STR71## in which:

R(1) is CF.sub.3 ;

one of the substituents R(2) and R(3) is hydrogen;

and the other substituent R(2) or R(3) in each case is --C(OH)(CH.sub.3)--CH.sub.2 OH, --CH(CH.sub.3)--CH.sub.2 OH or --C(OH)(CH.sub.3).sub.2 ;

R(4) is methyl, methoxy, Cl or CF.sub.3 ; and their pharmaceutically tolerable salts.

(DE 195 02 895, DE 44 30 212, EP 667 341, DE 44 04 183, EP 708 088, EP 723 963, EP 0 694 537, DE 44 21 495, EP 699 660, EP 699 663, EP 699 666, DE 43 37 611, EP 0719 766, WO 94/26709, WO 96 04 241, EP 726 254, U.S. Pat. No. 4,251,545, DE 35 02 629, WO 84/00875, Kumamoto et al., Pharm. Bull. [1966], 7-13; U.S. Pat. No. 3,780,027, JP 8225513; EP 743 301)

II. Also suitable are compounds of the formula ##STR72## in which:

W, Y and Z are a nitrogen atom or a carbon atom substituted by R(2) or R(3) or R(4);

R(1) is hydrogen, A, Hal, --CF.sub.3, --CH.sub.2 F, --CHF.sub.2, --CH.sub.2 CF.sub.3, --C.sub.2 F.sub.5, --CN, --NO.sub.2, -ethynyl, or an X-R';

A is alkyl having 1 to 6 carbon atoms;

Hal is F, Cl, Br or I;

X is oxygen, S or NR";

R' is H, A, HO--A--, HOOC--A--, (C.sub.3 -C.sub.7)-cycloalkyl, (C.sub.6 -C.sub.8)-cycloalkylalkyl, CF.sub.3, CH.sub.2 F, CHF.sub.2, CH.sub.2 --CF.sub.3, Ph, --CH.sub.2 --Ph or Het; or trisubstituted by A, OA, NR'R", Hal, CF.sub.3 ; having 1 to 4 nitrogen, oxygen and/or sulfur atoms, OH, OA, --X--R', --CN, --NO.sub.2, and/or carbonyl oxygen,

where Het is bonded via N or an alkylene chain C.sub.m H.sub.2m where m=zero to 6;

or

R' and R" together are alkylene having 4-5 carbon atoms, in which one CH.sub.2 group can also be replaced by oxygen, S, NH, N--A, N--Ph and N--CH.sub.2 --Ph;

R(2) and R(3) independently of one another are hydrogen, Hal, A, HO--A--, X--R', --C(.dbd.N--OH)--A, A--O--CO--(C.sub.1 -C.sub.4)-alkyl-, CN, N0.sub.2, COOH, halogen-substituted A, in particular CF.sub.3, CH.sub.2 F, CHF.sub.2, C.sub.2 F.sub.5, CH.sub.2 CF.sub.3, or S(O).sub.n R"';

R"' is A, Ph or --Het;

n is zero, 1 or 2;

or

R(2) and R(3) independently of one another are SO.sub.2 NR'R", Ph or --O--Ph, --O--CH.sub.2 --Ph, --CO--A, --CHO, --COOA, --CSNR'R", CONR'R", --CH.dbd.CH--COOH, --CH.dbd.CH--COOA, indenyl, indanyl, decahydronaphthyl, cyclopentenyl, dihydrothienyl, dihydrofuryl, heterobicyclyl, alkylthienyl, halothienyl, haloalkylthienyl, acylthienyl, halofuryl, haloalkylfuryl or pyrrolyl;

or

R(2) and R(3) independently of one another are R(5)--O--; R(5) is hydrogen, A, (C.sub.1 -C.sub.6)-alkenyl or (C.sub.3 -C.sub.7)-cycloalkyl;

R(4) is Ph, Het, --O--Het; CF.sub.3, S(O).sub.n R"', --SO.sub.2 NR'R", alk; ##STR73## or

two of the substituents R(1) to R(4) together are a group --O--CR(6)R(7)--CO--NR(8)--,

or ##STR74## where R(2) has the meaning indicated;

R(6), R(7), R(8) and R(9) independently of one another are H or A;

or

R(8) is (C.sub.5 -C.sub.7)-cycloalkyl;

or

R(9) is cyano;

alk is straight-chain or branched (C.sub.1 -C.sub.8)-alkyl or (C.sub.3 -C.sub.8)-cycloalkyl, which is unsubstituted or mono-, di- or trisubstituted by A;

or

alk is an ethenyl or ethynyl radical which is substituted by H, A, Ph or Het.

(EP 708 091, EP 622 356, JP 5-125085)

III. Likewise suitable are indoloylguanidine derivatives of the formula ##STR75## in which

R(2) is hydrogen, unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, OH, (C.sub.1 -C.sub.6)-alkyl--O--, an aromatic radical or a group --CH.sub.2 --R(20);

R(20) is (C.sub.2 -C.sub.6)-alkenyl or (C.sub.2 -C.sub.6)-alkynyl;

R(1) is 1 to 5 identical or different substituents, which are: hydrogen, unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.2 -C.sub.6)-alkynyl, (C.sub.3 -C.sub.7)-cycloalkyl, halogen, --NO.sub.2, (C.sub.2 -C.sub.8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, --COOH, (C.sub.2 -C6)-alkoxycarbonyl, an aromatic group or one of the following mentioned groups: --OR(3), --NR(6)R(7) or --S(O).sub.n R(40);

R(3) is hydrogen, (C.sub.1 -C.sub.8)-alkyl, substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, an aromatic radical or a group --CH.sub.2 --R(30); R(30) is alkenyl or alkynyl;

R(6) and R(7) independently of one another are hydrogen, unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, (C.sub.2 -C.sub.8)-alkanoyl, an arylalkanoyl group having up to 10 carbon atoms, an aroyl group having up to 11 carbon atoms, an aromatic group or --CH.sub.2 --R(60);

R(60) is (C.sub.2 -C.sub.6)-alkenyl or (C.sub.2 -C.sub.6)-alkynyl;

or

R(6) and R(7) together with the nitrogen atom are a 5-7-membered cyclic amine, which can additionally contain further heteroatoms in the ring;

n is zero, 1 or 2;

R(40) is unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, or an aromatic group, or a group ##STR76##

A is oxygen , --S(O).sub.n -- or --N(R50)--;

R(50) is hydrogen or (C.sub.1 -C.sub.8)-alkyl;

R' is hydrogen, unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, in which the ring represents a saturated 3-8-membered heterocycle having a nitrogen atom,

said substituted alkyl carries one or more groups selected from the group consisting of halogen, --OH, (C.sub.1 -C.sub.6)-alkoxy, --CN, --COOH, (C.sub.2 -C.sub.6)-alkoxycarbonyl, (C.sub.2 -C.sub.8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, --CONR(4)(R5), -C.sub.8)-alkyl;

or

R(4) and R(5) are connected to one another and together form a 5-7-membered cyclic amine which can additionally contain further heteroatoms in the ring,

or said substituted alkyl carries a group ##STR77## in which:

E is a nitrogen atom or a CH group;

R" is hydrogen, (C.sub.1 -C.sub.8)-alkyl which is unsubstituted or substituted by OH or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.6)-alkoxy, --CN, --COOH, (C.sub.2 -C.sub.6)-alkoxycarbonyl, (C.sub.2 -C.sub.8)-alkanoyl, aralkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, --NR(6)R(7), --CONR(4)R(5); -C.sub.8)-alkyl;

where the cyclic system of the formula ##STR78##

is a 3-8-membered saturated aliphatic or heterocyclic ring system having a nitrogen atom,

and where the aromatic groups mentioned are an aryl radical having up to 10 carbon atoms, a 5- or 6-membered heteroaryl radical having 1-4 nitrogen atoms, a 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms and a heteroatom which is oxygen or sulfur, or furyl, and where the aryl radicals mentioned can be unsubstituted or substituted by unsubstituted (C.sub.1 -C.sub.8)-alkyl or substituted (C.sub.1 -C.sub.8)-alkyl, halogen, --NO.sub.2, (C.sub.2 -C.sub.6)-alkoxycarbonyl, COOH, --OR(3), NR(6)R(7), --CONR(4)R(5), --SO.sub.2 NR(6)R(7) or S(O).sub.n R(40),

where R(1) and the guanidinocarbonyl radical can be in any desired position of the 5- or 6-membered ring of the indole system, and the appropriate pharmaceutically tolerable salts. (WO 95 04052)

IV. Additionally suitable are heterocyclic guanidine derivatives of the formula ##STR79## in which:

X is --O--, --S--, --NH--, --N[(C.sub.1 -C.sub.4)-alkyl]- or --N(phenyl)-;

R(1), R(2) and R(3) are hydrogen, halogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkyl--O--, phenyl, benzyl;

or

two of the substituents R(1), R(2) and R(3) together with one side of the benzo system are a 4-6-membered carbocyclic ring;

R(4) and R(5) independently of one another are hydrogen, (C.sub.1 -C.sub.12)-alkyl, benzhydryl, aralkyl, groups halogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkyl--O-- or --CF.sub.3, --(CH.sub.2).sub.m --CH.sub.2 --T,

m is zero to 3;

T is --CO--O--T(1);

T(1) is hydrogen or (C.sub.1 -C.sub.4)-alkyl;

Cy is a benzo-fused saturated or dihydro-5-membered ring heterocycle ##STR80##

a pyrazole or imidazole ring of the formula ##STR81## a naphthyl radical or a dihydro- or tetrahydronaphthyl radical ##STR82## a 2-,3- or 4-pyridyl radical ##STR83##

z is N-- or CH;

a thienyl radical ##STR84##

R(6) is hydrogen, halogen hydroxyl, (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.10)-alkyl--O--, phenoxy, (C.sub.1 -C.sub.10)-alkyloxymethyloxy- or --(O).sub.n S--R(9);

R(9) is (C.sub.1 -C.sub.10)-alkyl, thienyl, pyridyl, thiazolyl, thiadiazolyl, imidazolyl, pyrazolyl or phenyl, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-alkyl--O--;

R(7) and R(8) are hydrogen, halogen, hydroxyl, (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.10)-alkyl--O--, phenyl, phenoxy or (C.sub.1 -C.sub.10)-alkoxymethyloxy;

or

Cy is phenyl, which is unsubstituted or is mono- or disubstituted by halogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-alkyl--O--;

or

Cy is --Gr--Am;

Gr is --R(13)--R(12)--(CH.sub.2).sub.q -C[W][W(1)]--(CH.sub.2).sub.q --; R(13)R(14)-- or

--R(15)--;

R(12) is a single bond, --O--, --(O).sub.n S--, --CO-- or --CONH--;

R(13) is a single bond, phenyl, thienyl, pyridyl, thiazolyl, thiadiazolyl, imidazolyl or pyrazolyl;

R(14) is a single bond or SO.sub.2 --;

R(15) is (C.sub.2 -C.sub.10)-alkenyl or (C.sub.2 -C.sub.10)-alkynyl;

W and W(1) independently of one another are hydrogen, (C.sub.1 -C.sub.4)-alkyl;

or

W and W(1) cyclically connected to one another are a (C.sub.3 -C.sub.8)-hydrocarbon ring;

q and q' are zero to 9;

Am is --NR(10)R(11); R(10) is hydrogen, (C.sub.1 -C.sub.4)-alkyl or benzyl, R(1 1) is (C.sub.1 -C.sub.4)-alkyl, phenyl or benzyl;

or -C.sub.5)-alkoxycarbonyl, (C.sub.2 -C.sub.4)-hydroxyl-alkylene or benzyl;

or

Am is pyrrolyl, pyridyl, pyrazolyl, morpholinyl, dihydropyridyl, tetrahydropyridyl, quinuclidinyl, imidazolyl, 3-azabicyclo[3.2.1]octyl,

or

Am is azabicyclo[3.2.2]nonyl;

or

Am is a piperazine group of the formula ##STR85##

R(16) is hydrogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, phenyl, tolyl, methoxyphenyl, halophenyl, diphenylmethylene, benzyl or pyridyl;

or

Am is an azido group --(O)t--(CH2).sub.q --C[W][W(1)]--(CH2)q'--N.sub.3 ;

t is zero or 1;

where W and W(1) have the previously indicated meaning;

and the optical enantiomers and the pharmacologically tolerable salts.

V. Additionally suitable are the guanidine compounds such as are described in

EP-743 301 (DE 195 17 848), EP 758 644 (DE 195 29 612), EP 760 365 (DE 195 31 138) ##STR86## where R1.dbd.R2 is H, halo, alkyl, CN, NO.sub.2, perfluoroalkyl, SO.sub.n CF.sub.3 ; R3 is CH.dbd.CH.sub.2, CH.sub.2 --CH.dbd.CH.sub.2, CH.sub.2 --CH.sub.2 --CH.dbd.CH.sub.2, cycloalkenyl, cycloalkenylalkyl; R4 is alkyl, (substituted) phenyl,

or as described in DE 195 48 708, WO 97 25 310, WO 97 27 183, DE 196 01 303, EP 787 728, JP 82 25 513, JP 090 59 245, JP 090 67 332, JP 690 67 340, WO 97 11 055 and EP 743 301.

Compounds which are particularly suitable for the use according to the invention are those selected from the group consisting of the compounds

I. (HOE 89/F 288 - U.S. Pat. No. 5,292,755)

a) benzoylguanidines of the formula I ##STR87## in which:

R(1) or R(2) is R(6)--S(O).sub.n -- or R(7)R(8)N--O.sub.2 S--;

and the other substituent R(1) or R(2) in each case is H, F, Cl, Br, (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy or phenoxy, group consisting of fluorine, chlorine, methyl and methoxy;

or the other substituent R(1) or R(2) in each case is R(6)--S(O).sub.n or R(7)R(8)N--;

n is zero, 1 or 2; cyclopentylmethyl, cyclohexylmethyl or phenyl, group consisting of fluorine, chlorine, methyl and methoxy;

R(7) and R(8) identically or differently are H or (C.sub.1 -C.sub.6)-alkyl;

or

R(7) is phenyl--(CH.sub.2).sub.m ;

m is 1-4;

or

R(7) is phenyl, which is unsubstituted or substituted by 1-2 substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;

or

R(7) and R(8) together are a straight-chain or branched (C.sub.4 -C.sub.7)-chain, where the chain can additionally be interrupted by O, S or NR(9);

R(9) is H or methyl;

or

R(7) and R(8) together with the nitrogen atom to which they are bonded, are a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;

R(3), R(4) and R(5) independently of one another are H or (C.sub.1 -C.sub.2)-alkyl,

or

R(3) and R(4) together are a (C.sub.2 -C.sub.4)-alkylene chain;

or

R(4) and R(5) together are a (C.sub.4 -C.sub.7)-alkylene chain; and their pharmaceutically tolerable salts; (HOE 92/F 34 - U.S. Pat. No. 5,373,924)

b) benzoylguanidines of the formula I ##STR88## in which:

R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --;

m is zero, 1 or 2;

R(4) and R(5) are C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.6 -alkenyl or --C.sub.n H.sub.2n --R(7);

n is zero, 1, 2, 3 or 4; substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9);

or

R(5) is H;

R(6) is H or C.sub.1 -C.sub.4 -alkyl,

or

R(5) and R(6) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by an O, S, NH, N--CH.sub.3 or N-benzyl;

R(2) is hydrogen, F, Cl, Br, (C.sub.1 -C.sub.4)-alkyl-, O--(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --X--R(10);

m is zero or 1;

p is 1, 2 or 3;

x is O, S or NR(11);

R(10) is H, C.sub.1 -C.sub.6 -alkyl, C.sub.5 -C.sub.7 -cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12);

n is zero, 1, 2, 3 or 4; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9);

or group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl;

R(3) is defined as R(1), or is C.sub.1 -C.sub.6 -alkyl, nitro, cyano, trifluoromethyl, F, Cl, Br, I or --X--R(10);

x is O, S or NR(11);

R(10) is H, C.sub.1 -C.sub.6 -alkyl, C.sub.5 -C.sub.7 -cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12);

n is zero to 4;

R(12) is phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy und NR(8)R(9);

R(11) is C.sub.1 -C.sub.3 -alkyl,

or

R(10) and R(11) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by O, S, NH, N-CH.sub.3 or N-benzyl;

and their pharmaceutically tolerable salts; (HOE 92/F 303 K - EP-A 589 336, NZ 248 703)

f) benzotylguanidines of the formula I ##STR89## in which:

R(1) or R(2) is R(3)--S(O).sub.n -- or R(4)R(5)N--SO.sub.2 --

the other substituent R(1) or R(2) in each case benzyloxy or phenoxy, the group consisting of fluorine, chlorine, methyl, methoxy, hydroxyl or benzyloxy, cyclopentylmethyl, cyclohexylmethyl or phenyl, the group consisting of fluorine, chlorine, methyl and methoxy;

R(4) and R(5) identically or differently, are H or C.sub.1 -C.sub.6 -alkyl;

for

R(4) is phenyl-(CH.sub.2).sub.m --;

m is 1, 2, 3 or 4;

or

R(4) is phenyl, which is unsubstituted or carries one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy;

or

R(4) and R(5) together are a straight-chain or branched C.sub.4 -C.sub.7 -chain, where the chain can additionally be interrupted by O, S or NR(6), R(6) is H or methyl;

or

R(4) and R(5) together with the nitrogen atom to which they are bonded, are a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system;

n is zero, 1 or 2;

and their pharmaceutically tolerable salts; (HOE 92/F 411 - NZ 250 450, EP 603 650)

k) benzoylguanidines of the formula I ##STR90## in which:

one of the substituents R(1), R(2), R(3) or R(4):

is an amino group ##STR91##

R(5) is hydrogen or C(.sub.1-6 -alkyl;

n is zero, 1, 2, 3 or 4;

R(6) is H or C(.sub.1-4)-alkyl;

in which one CH.sub.2 group can be replaced by 1 sulfur atom or a group NR(7);

R(7) is hydrogen, methyl or ethyl;

or

R(6) is C(.sub.3-8)-cycloalkyl or phenyl, which is unsubstituted or carries 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, methyl, methoxy, --NR(8)R(9);

or

R(5) and R(6) together with the nitrogen atom are a 5-, 6- or 7-membered ring, in which 1 carbon atom can be replaced by oxygen, S or NR(10);

R(10) is H, C(.sub.1-3)-alkyl or benzyl;

and the other substituents R(1), R(2), R(3), R(4) in each case are: hydrogen, F, Cl, Br, I, CN, CF.sub.3, NO.sub.2, CF.sub.3 --O--, C.sub.m F.sub.2m+1 --CH.sub.2 --O-- or R(11)--C.sub.q H.sub.2q --X.sub.p --;

m is 1, 2 or 3;

q is zero, 1, 2, 3 or 4;

p is zero or 1;

X is oxygen or NR(12); R(12) is H or C(1-3)-alkyl;

R(11) is hydrogen, C(.sub.1-6)-alkyl, C(.sub.3-8)-cycloalkyl or phenyl, which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH.sub.3, CH.sub.3 --O-- and NR(13)R(14);

and their pharmaceutically tolerable salts; (93/F 054 - NZ 250 919, EP-A 612 723)

m) benzoylguanidines of the formula I ##STR92## in which:

R(1), R(2), R(3) are hydrogen, F, Cl, Br, I or (C.sub.1 -C.sub.12)-alkyl;

one of the substituents R(1), R(2) or R(3) is N.sub.3, CN, OH or (C.sub.1 -C.sub.10)-alkyloxy, if at least one of the remaining substituents R(1), R(2) or R(3) is a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms;

or

one of the substituents R(1), R(2) or R(3)

is R(4)-C.sub.n H.sub.2n --O.sub.m --;

m is zero or 1;

n is zero, 1, 2 or 3;

R(4) is C.sub.p F.sub.2p+1 ;

p is 1, 2 or 3, if n is zero or 1;

or

R(4) is (C.sub.3 -C.sub.12)-cycloalkyl, phenyl, pyridyl, quinolyl or isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted by a substituent selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(5)R(6);

R(5) and R(6) are hydrogen or (C.sub.1 -C.sub.4)-alkyl;

or one of the substituents R(1), R(2) or R(3) is --C.tbd.CR(5) or --C[R(6)].dbd.CR(5);

R(5) is phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, hydroxyl, amino, methylamino and dimethylamino,

(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted as phenyl,

or

R(5) is (C.sub.1 -C.sub.6)-alkyl, which is unsubstituted or substituted by 1-3 OH;

or

R(5) is (C.sub.3 -C.sub.8)-cycloalkyl,

R(6) is hydrogen or methyl; and their pharmacologically acceptable salts; (93/F 153 - EP-A 627 413, NZ 260 660)

o) benzoylguanidines of the formula I ##STR93## in which:

R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.tbd.N, X.sub.o --(CH.sub.2).sub.p --(CF.sub.2).sub.q --CF.sub.3, R(5)--SO.sub.m, R(6)--CO-- or R(6)R(7)N--SO.sub.2 --, where

X is oxygen, S or NR(14);

m is zero, 1 or 2;

o is zero or 1;

p is zero, 1 or 2;

q is zero, 1, 2, 3, 4, 5 or 6;

R(5) and R(6) are (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl, -C.sub.n H.sub.2n -R(8) or CF.sub.3 ;

n is zero, 1, 2, 3 or 4; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10);

or

R(6) is H;

R(7) is H or (C.sub.1 -C.sub.4)-alkyl;

or

R(6) and R(7) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; ##STR94## Y is oxygen, --S-- or --NR(12)--;

R(11) and R(12) are hydrogen or (C.sub.1 -C.sub.3)-alkyl;

h is zero or 1;

i, j and k independently are zero, 1, 2, 3 or 4;

but where h, i and k are not simultaneously zero,

R(3) is defined as R(1), or is (C.sub.1 -C.sub.6)-alkyl or --X--R(13);

x is oxygen, S or NR(14);

R(14) is H or (C.sub.1 -C.sub.3)-alkyl;

R(13) is H, (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or --C.sub.b H.sub.2b --R(15);

b is zero, 1, 2, 3 or 4;

or

R(13) and R(14) together are 4 or 5 methylene groups, where one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10);

R(4) is hydrogen, --OR(16) or --NR(16)R(17);

R(16) and R(17) independently are hydrogen or (C.sub.1 -C.sub.3)-alkyl; and their pharmaceutically tolerable salts;

(HOE 93/F 223 K - EP 639 5 3, NZ 264 130)

r) benzo-fused 5-membered ring heterocycles of the formula I ##STR95## in which:

x is N or CR(6);

Y is oxygen, S or NR(7);

A, B together are a bond

or

A, B are both hydrogen, if X is CR(6) and Y is NR(7) simultaneously; one of the substituents R(1) to R(6) is a --CO--N.dbd.C(NH.sub.2).sub.2 group; the other substituents R(1) to R(6) in each case are hydrogen, F, Cl, Br, I or (C.sub.1 -C.sub.6)-alkyl;

up to two of the other substituents R(1) to R(6) are CN, NO.sub.2, N.sub.3, (C.sub.1 -C.sub.4)-alkyloxy or CF.sub.3 ;

up to one of the other substituents is R(8)--C.sub.n H.sub.2n --Z--;

n is zero to 10; branched and where one carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom;

R(8) is hydrogen, (C.sub.2 -C.sub.6)-alkenyl or (C.sub.3 -C.sub.10)-cycloalkyl, group, or can contain an ethylene group --CH.dbd.CH--, and in which one methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom;

or

R(8) is phenyl, the group consisting of F, Cl, Br, I, CF.sub.3, CH.sub.3 --S(O).sub.s -- or R(9)--W.sub.y --;

s is zero, 1 or 2;

R(9) is H, methyl, ethyl,

W is oxygen or NR(10); R(10) is H or methyl;

y is zero or 1;

or

R(8) is C.sub.m F.sub.2m+1 ;

m is 1 to 3;

or

R(8) is 1- or 2-naphthyl, pyridyl, quinolyl or isoquinolyl;

Z is --CO--, --CH.sub.2 -- or --[CR(11)(OH)].sub.q --;

q is 1, 2 or 3;

R(11) is H or methyl;

or

z is oxygen or --NR(12)--;

R(12) is H or methyl;

or

Z is --S(O).sub.s --;

s is zero, 1 or 2;

or

Z is --SO.sub.2 --NR(13)--;

R(13) is H or (C.sub.1 -C.sub.4)-alkyl;

R(7) is hydrogen, (C.sub.1 -C.sub.10)-alkyl, (C.sub.2 -C.sub.10)-alkenyl or R(8)-C.sub.n H.sub.2n --; and their pharmaceutically tolerable salts;

(HOE 94/F 134 - EP-A 686 627, NZ 272 103)

z) benzoylguanidines of the formula I ##STR96## in which:

R(1) is R(6)--SO.sub.m ;

m is zero, 1 or 2;

R(6) is perfluoroalkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, which is straight-chain or branched;

R(2) and R(3) independently of one another are hydrogen, F, Cl, Br, I, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, group consisting of F, Cl, methyl and methoxy;

or

R(2) and R(3) independently of one another are pyrrol-1-yl, pyrrol-2-yl- or pyrrol-3-yl, from the group consisting of F, Cl, Br, I, CN, alkanoyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxycarbonyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, formyl, carboxyl, CF.sub.3, methyl and methoxy;

R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2 or 3 carbon atoms, F, Cl, Br, I, CN, OR(7), NR(8)R(9) or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ;

R(7), R(8) and R(9) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

n is zero or 1;

o is zero, 1 or 2;

and their pharmacologically acceptable salts; (HOE 95/F 007 K - EP-A 723 956, NZ 280 887)

ag) benzoylguanidines of the formula I ##STR97## in which:

one of the three substituents R(1), R(2) and R(3) is R(6)--A--B--D--;

R(6) is a basic protonatable radical, i.e. an amino group --NR(7)R(8), an amidino group R(7)R(8)N--C[.dbd.N--R(9)]-- or a guanidino group ##STR98##

R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

or

R(7) and R(8) together are C.sub.a H.sub.2a ;

a is 4, 5, 6 or 7;

where if a=5, 6 or 7 a methylene group of the group C.sub.a H.sub.2a can be replaced by a heteroatom group O, SO.sub.m or NR(11),

or

R(8) and R(9) or R(9) and R(10) or R(7) and R(10) are a group C.sub.a H.sub.2a ;

a is 2, 3, 4 or 5;

where if a=3, 4 or 5 a methylene group of the group C.sub.a H.sub.2a can be replaced by a heteroatom group O, SO.sub.m or NR(11);

m is zero, 1 or 2;

R(1 1) is hydrogen or methyl;

or

R(6) is a basic heteroaromatic ring system having 1-9 carbon atoms;

A is C.sub.b H.sub.2b ;

b is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; where in the group C.sub.b H.sub.2b one or two methylene groups can be replaced by one of the groupings selected from the group consisting of --O--, --CO--, --CH[OR(20)]--, --SO.sub.m --, --NR(20)--, --NR(20)--CO--, --NR(20)--CO--NH--, --NR(20)--CO--NH--SO.sub.2 -- ##STR99## and --SO.sub.aa [NR(19)].sub.bb --;

and where in the group C.sub.b H.sub.2b a methylene group can be replaced by --CH--R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring;

aa is 1 or 2;

bb is 0 or 1;

aa+bb=2;

B is a phenylene or naphthylene radical ##STR100##

R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF.sub.3 or --SO.sub.w --R(14);

R(14) is methyl or NR(15)R(16);

R(15) and R(16) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;

w is zero, 1 or 2;

D is --C.sub.d H2d--X.sub.f --;

d is zero, 1, 2, 3 or 4;

x is --O--, --CO--, --CH[OR(21)]--, --SO.sub.m -- or --NR(21)--;

f is zero or 1;

R(21) is hydrogen or methyl;

m is zero, 1 or 2;

and the other substituents R(1) and R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, --CN, --(C.sub.1 -C.sub.8)-alkyl, --(C.sub.2 -C.sub.8)-alkenyl, --NR(35)R(36) or R(17)--C.sub.g H.sub.2g --Z.sub.h --;

g is zero, 1, 2, 3 or 4;

h is zero or 1;

R(35) and R(36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

or

R(35) and R(36) together are 4-7 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl;

Z is --O--, --CO--, --SO.sub.v --,--NR(18)--, --NR(18)--CO--, --NR(18)--CO--NH-- or --NR(18)--SO.sub.2 --;

R(18) is hydrogen or methyl;

v is zero, 1 or 2;

R(17) is hydrogen, cycloalkyl having 3, 5 or 6 carbon atoms or C.sub.k F.sub.2k+1 --;

k is 1, 2 or 3,

or

R(17) is pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl and methoxy;

or

R(17) -is (C.sub.3 -C.sub.8)-cycloalkyl or phenyl, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, hydroxyl, methoxy, --NR(37)R(38), CH.sub.3 SO.sub.2 -- and H.sub.2 NO.sub.2 S--;

R(4) and R(5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or --C.sub.r F.sub.2r+1 ; having 1, 2 or 3 carbon atoms;

r is 1, 2, 3 or 4;

and their pharmacologically tolerable salts; (HOE 95/F 173 - NZ 299 052)

am) substituted cinnamic acid guanidides of the formula I ##STR101## in which:

at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is

--X.sub.a --Y.sub.b --L.sub.n --U;

x is CR(16)R(17), O, S or NR(18);

R(16), R(17) and R(18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

a is zero or 1;

Y is alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkylene-T having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group; is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(21)R(22); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

b is zero or 1;

L is O, S, NR(23) or C.sub.k H.sub.2k ;

k is 1, 2, 3, 4, 5, 6, 7 or 8;

n is zero or 1;

U is NR(24)R(25) or an N-containing heterocycle having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms; 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;

or

R(24) and R(25) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

where the N-containing heterocycles are N- or C-bridged and are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28);

R(23), R(27) and R(28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, I, CN, --O.sub.n --C.sub.m H.sub.2m+1,

--O.sub.p --(CH.sub.2).sub.s --C.sub.q F.sub.2q+1 or --C.sub.r H.sub.2r R(10);

n is zero or 1;

m is zero, 1, 2, 3, 4, 5, 6, 7 or 8;

p is zero or 1;

q is 1, 2, 3, 4, 5, 6, 7 or 8;

s is zero, 1, 2, 3 or 4;

r is zero, 1, 2, 3 or 4;

R(10) phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(11)R(12); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

R(6) and R(7) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl,

which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms;

and their pharmaceutically tolerable salts; (HOE 96/F 226 - EP 825 178)

bd) phenyl-substituted alkenylcarboxylic acid guanidides of the formula I ##STR102## in which:

T is ##STR103##

R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C.sub.1 -C.sub.4)-alkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, (C.sub.3 -C.sub.8)-cycloalkyl oder NR(7)R(8)

r is zero or 1;

a is zero, 1, 2, 3 or 4;

b is 1, 2, 3 or 4;

R(6) is (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-perfluoroalkyl, (C.sub.3 -C.sub.6)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoro-alkyl;

or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl;

R(B), R(C) and R(D) independently are defined as R(A);

x is zero, 1 or 2;

y is zero, 1 or 2;

R(F) is hydrogen, F, Cl, Br, I, CN, OR(12), (C.sub.1 -C.sub.8)-alkyl, O.sub.p (CH.sub.2).sub.f C.sub.g F.sub.2g+1, (C.sub.3 -C.sub.8)-cycloalkyl or (C.sub.1 -C.sub.9)-heteroaryl;

p is zero or 1;

f is zero, 1, 2, 3 or 4;

g is 1, 2, 3, 4, 5, 6, 7 or 8; (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl;

R(E) is defined independently as R(F);

R(1) is defined independently as T;

or

R(1) is hydrogen, --O.sub.k C.sub.m H.sub.2m+1, --O.sub.n (CH.sub.2).sub.p C.sub.q F.sub.2q+1, F, Cl, Br, I, CN, --(C.dbd.O)-- N.dbd.C(N H.sub.2).sub.2, --So.sub.r R(17), --SO.sub.r2 N R(31) R(32), --O.sub.u (CH.sub.2).sub.v C.sub.6 H.sub.5, --O.sub.u2 --(C.sub.1 -C.sub.9)-heteroaryl or --S.sub.u2 --(C.sub.1 -C.sub.9)-heteroaryl;

k is zero or 1;

m is zero, 1, 2, 3, 4, 5, 6, 7 or 8;

n is zero or 1;

p is zero, 1, 2, 3 or 4;

q is 1, 2, 3, 4, 5, 6, 7 or 8;

r is zero, 1 or 2;

r2 is zero, 1 or 2;

R(31) and R(32) independently of one another are hydrogen, (C.sub.1 -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-perfluoroalkyl;

or

R(31) and R(32) are, together, 4 or 5 methylene groups of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl;

R(17) is (C.sub.1 -C.sub.8)-alkyl;

u is zero or 1;

u2 is zero or 1;

v is zero, 1, 2, 3 or 4;

where the phenyl nucleus is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w NR(21)R(22), NR(18)R(19) and (C.sub.1 -C.sub.9)-heteroaryl; -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl;

w is 1, 2, 3 or 4;

where the heterocycle of the (C.sub.1 -C.sub.9)-heteroaryl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl or methoxy;

R(2), R(3), R(4) and R(5) independently of one another are defined as R(1),

or

R(1) and R(2) or R(2) and R(3) in each case together are --CH--CH.dbd.CH--CH--, which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w2 NR(24)R(25) and NR(26)R(27); -C.sub.4)-perfluoroalkyl;

w 2 is 1, 2, 3 or 4;

the radical T being present in the molecule at least twice, but only three times at most;

and their pharmaceutically tolerable salts.

Very particularly suitable compounds are those which are selected from the group consisting of

3-dimethylamino-5-trifluoromethylbenzoylguanidine,

3-phenyl-5-trifluoromethylbenzoylguanidine,

3-isopropyl-4-fluoro-5-trifluoromethylbenzoylguanidine,

3-chloro-5-(1-pyrrolyl)benzoylguanidine,

3-chloro-5-trifluoromethylbenzoylguanidine,

3-dimethylamino-5-(1-pyrrolyl)benzoylguanidine,

3-dimethylamino4-tert-butylbenzoylguanidine,

4-(3-chloroanilino)-3-methylsulfonylbenzoylguanidine,

4-(4-aminoethylphenoxy)-3-methylsulfonylbenzoylguanidine,

4-(4-aminoethylsulfonylmethylphenoxy)-3-trifluoromethylbenzoylguanidine,

4-(4-aminoethylthiophenoxy)-3-trifluoromethylbenzoylguanidine,

3,5-di-tert-butylbenzoylguanidine,

3,5-di-tert-butyl4-hydroxybenzoylguanidine,

5-chloro-2-indoloylguanidine,

3,5-dichloro-2-indoloylguanidine,

5-chloro-3-phenylthio-2-indoloylguanidine,

5-chloro-3-phenylsulfonyl-2-indoloylguanidine,

5-methoxy-3-isopropyl-2-indoloylguanidine,

4-benzyloxy-2-indoloylguanidine,

5-chloro-1-(4-picolyl)-2-indoloylguanidine,

2-(4-hydroxyphenyl)4-benzimidazolylguanidine,

n-{3-[3-(3-guanidino-2-methyl-3-oxopropenyl)phenyl]-2-methylacryloyl}guandi ne,

and their pharmacologically tolerable salts.

## Claims

1. A method for the treatment or prophylaxis of a disease which is caused by protozoa, comprising administering to a patient in need thereof a medicament comprising a pharmaceutically effective amount of a Na.sup.+ /H.sup.+  exchange inhibitor selected from the group consisting of ##STR104## in which: R(1) or R(2) is R(6)--S(O).sub.n -- or R(7)R(8)N--O.sub.2 S--; (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy or phenoxy, group consisting of fluorine, chlorine, methyl and methoxy; or the other substituent R(1) or R(2) in each case is R(6)--S(O).sub.n or R(7)R(8)N--; cyclopentylmethyl, cyclohexylmethyl or phenyl, group consisting of fluorine, chlorine, methyl and methoxy; or or selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -C.sub.7)-chain, where the chain can additionally be interrupted by O, S or NR(9); R(9) is H or methyl; or a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; -C.sub.2)-alkyl, or or or a pharmaceutically tolerable salt thereof; ##STR105## in which: R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); R(8) and R(9) are H or C.sub.1 -C.sub.4 -alkyl; or or group can be replaced by an O, S, NH, N-CH.sub.3 or N-benzyl; C.sub.p F.sub.2p+1 or --X--R(10); cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl; trifluoromethyl, F, Cl, Br, I or --X--R(10); cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy und NR(8)R(9); or group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl; or a pharmaceutically tolerable salt thereof; ##STR106## in which: R(1) is F, Cl, Br, I, C.sub.1 -C.sub.6 -alkyl or --X--R(6); cyclohexylmethyl, cyclopentylmethyl, --(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --C.sub.n H.sub.2n --R(8); selected from the group consisting of the groups F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or group can be replaced by O, S, NH, N-CH.sub.3 or N-benzyl; cyclohexylmethyl, cyclopentylmethyl, --(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --C.sub.n H.sub.2n --R(8);

2. The method as claimed in claim 1, wherein the disease is tropical malaria.

3. The method as claimed in claim 1, wherein the disease is tertian malaria.

4. The method as claimed in claim 1, wherein the disease is quartan malaria.

5. The method as claimed in claim 1, wherein the disease is toxoplasmosis.

6. The method as claimed in claim 1, wherein the disease is coccidiosis.

7. The method as claimed in claim 1, wherein the disease is intestinal sarcosporidosis.

8. The method as claimed in claim 1, wherein the disease is cryptosporidosis.

9. The method as claimed in claim 1, wherein the disease is Chargas' disease.

10. The method as claimed in claim 1, wherein the disease is leishmaniasis.

11. The method according to claim 10, wherein the leishmaniasis is cutaneous or visceral.

12. The method as claimed in claim 1, wherein the patient is an animal which is infected by animal-pathogenic protozoa.

13. The method as claimed in any of claims 1, 2-12, wherein the Na.sup.+ /H.sup.+  exchange inhibitor is selected from the group consisting of ##STR107## in which: R(1) or R(2) is R(6)--S(O).sub.n -- or R(7)R(8)N--O.sub.2 S--; (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy or phenoxy, group consisting of fluorine, chlorine, methyl and methoxy; R(7)R(8)N--; cyclopentylmethyl, cyclohexylmethyl or phenyl, group consisting of fluorine, chlorine, methyl and methoxy; or or selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -C.sub.7)-chain, where the chain can additionally be interrupted by O, S or NR(9); or a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; -C.sub.2)-alkyl, or or or a pharmaceutically tolerable salt thereof; ##STR108## in which: R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; -C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or or group can be replaced by an 0, S, NH, N--CH.sub.3 or N-benzyl; C.sub.p F.sub.2p+1 or --X--R(10); cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or group can be replaced by O, S, NH, N-CH.sub.3 or N-benzyl; R(3) is defined as R(1), or is C.sub.1 -C.sub.6 -alkyl, nitro, cyano, trifluoromethyl, F, Cl, Br, I or --X--R(10); cyclohexylmethyl, cyclopentylmethyl or --C.sub.n H.sub.2n --R(12); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy und NR(8)R(9); or group can be replaced by O, S, NH, N-CH.sub.3 or N-benzyl; or a pharmaceutically tolerable salt thereof; ##STR109## in which: R(1) or R(2) is R(3)--S(O).sub.n -- or R(4)R(5)N--SO.sub.2 -- the other substituent R(1) or R(2) in each case benzyloxy or phenoxy, which is unsubstituted or carries one to three substituents selected from the group consisting of fluorine, chlorine, methyl, methoxy, hydroxyl or benzyloxy, cyclopentylmethyl, cyclohexylmethyl or phenyl, the group consisting of fluorine, chlorine, methyl and methoxy; or or selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -chain, where the chain can additionally be interrupted by O, S or NR(6), or a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; or a pharmaceutically tolerable salt thereof; ##STR110## in which: one of the substituents R(1), R(2), R(3) or R(4): ##STR111## R(5) is hydrogen or C(.sub.1-6)-alkyl; n is zero, 1, 2, 3 or 4; NR(7); or 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, methyl, methoxy, --NR(8)R(9); or ring, in which 1 carbon atom can be replaced by oxygen, S or NR(10); and the other substituents R(1), R(2), R(3), R(4) in each case are: hydrogen, F, Cl, Br, I, CN, CF.sub.3, NO.sub.2, CF.sub.3 --O--, C.sub.m F.sub.2m+1 --CH.sub.2 --O-- or R(11)-- which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH.sub.3, CH.sub.3 --O-- and NR(13)R(14); or a pharmaceutically tolerable salt thereof; ##STR112## in which: R(1), R(2), R(3) are hydrogen, F, Cl, Br, I or (C.sub.1 -C.sub.12)-alkyl; -C.sub.10)-alkyloxy, if at least one of the remaining substituents R(1), R(2) or R(3) is a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms; or or isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted by a substituent selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(5)R(6); --C[R(6)].dbd.CR(5); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, hydroxyl, amino, methylamino and dimethylamino, phenyl, or 1-3 OH; or or a pharmacologically acceptable salt thereof; ##STR113## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.tbd.N, X.sub.o --(CH.sub.2).sub.p --(CF.sub.2).sub.q --CF.sub.3, R(5)--SO.sub.m, R(6)--CO-- or R(6)R(7)N--SO.sub.2 --, where --C.sub.n H.sub.2n --R(8) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; ##STR114## Y is oxygen, --S-- or --NR(12)--; R(11)and R(12) are hydrogen or (C.sub.1 -C.sub.3)-alkyl; --C.sub.b H.sub.2b --R(15); or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or a pharmaceutically tolerable salt thereof; ##STR115## in which: X is N or CR(6); or the substituents R(1) to R(6) is a --CO--N.dbd.C(NH.sub.2).sub.2 group; or (C.sub.1 -C.sub.6)-alkyl; (C.sub.1 -C.sub.4)-alkyloxy or CF.sub.3 ; branched and where one carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom; -C.sub.10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group --CH.dbd.CH--, and in which one methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom; or substituents selected from the group consisting of F, Cl, Br, I, CF.sub.3, CH.sub.3 --S(O).sub.s -- or R(9)-W.sub.y --; or or or or or R(8)-C.sub.n H.sub.2n --; or a pharmaceutically tolerable salt thereof; ##STR116## in which: R(1 ) is 13(6)--SO.sub.m ; straight-chain or branched; alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or.4 carbon atoms or phenoxy, group consisting of F, Cl, methyl and methoxy; or which is not substituted or is substituted by I to 4 substituents selected from the group consisting of F, Cl, Br, I, CN, alkanoyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxycarbonyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, formyl, carboxyl, CF.sub.3, methyl and methoxy; or 3 carbon atoms, F, Cl, Br, I, CN, OR(7), NR(8)R(9) or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms; or a pharmacologically acceptable salt thereof; ##STR117## in which: one of the three substituents R(1), R(2) and R(3) is R(6)--A--B--D--; amidino group R(7)R(8)N--C[.dbd.N--R(9)]-- or a guanidino group ##STR118## R(7), R(8), a R(9) and R(10) in dependently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or replaced by a heteroatom group O, SO.sub.m or NR(11), or replaced by a heteroatom group O, SO.sub.m or NR(11); or replaced by one of the groupings selected from the group consisting of --O--, --CO--, --CH[OR(20)]--, --SO.sub.m --, --NR(20)--, --NR(20)--CO--, --NR(20)--CO--NH--, --NR(20)--CO--NH--SO.sub.2 -- ##STR119## and --SO.sub.aa [NR(19)].sub.bb --; and where in the group C.sub.b H.sub.2b a methylene group can be replaced by --CH--R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring; ##STR120## R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF.sub.3 or --SO.sub.w --R(14); 1, 2, 3 or 4 carbon atoms; and the other substituents R(1) and R(2) and R(3) in each case independently of one another are hydrogen, F, Cl, Br, I, --CN, --(C.sub.1 -C.sub.8)-- alkyl, --(C.sub.2 -C.sub.8)-alkenyl, --NR(35)R(36) or R(17)-C.sub.g H.sub.2g --Z.sub.h --; 1, 2, 3, 4, 5 or 6 carbon atoms; or group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl; --NR(18)--CO--NH-- or --NR(18)--SO.sub.2 --; F.sub.2k+1 --; or or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl and methoxy; or or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, hydroxyl, methoxy, --NR(37)R(38), CH.sub.3 SO.sub.2 -- and H.sub.2 NO.sub.2 S--; 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or --C.sub.r F.sub.2r+1 ; having 1, 2 or 3 carbon atoms; ##STR121## in which: at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group; is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(21)R(22); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; 8 or 9 carbon atoms; 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; and the other substituents R(1), R(2), R(3), R(4) and R(5) in each case independently of one another are H, F, Cl, Br, I, CN, --O.sub.n --C.sub.m H.sub.2m+1, --O.sub.p -- (CH.sub.2).sub.s --C.sub.q F.sub.2q+1 or --C.sub.r H.sub.2r R(10); where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(11)R(12); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; or a pharmaceutically tolerable salt thereof; ##STR122## in which: T is ##STR123## R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C.sub.1 -C.sub.4)-alkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, (C.sub.3 -C.sub.8)-cycloalkyl oder NR(7)R(8) (C.sub.3 -C.sub.6)-alkenyl, being substituted or being substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(l0); -C.sub.4)-perfluoro-alkyl; or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or (C.sub.1 -C.sub.9)-heteroaryl; (C.sub.3 -C.sub.8)-alkenyl, being substituted or being substituted by 1-3 substituents selected from the group corisisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl; or C.sub.q F.sub.2q+1, F, Cl, Br, I, CN, --(C.dbd.O)-- N.dbd.C(N H.sub.2).sub.2, --SO.sub.r R(17), --SO.sub.r2 N R(31)R(32), --O.sub.u (CH.sub.2).sub.v C.sub.6 H.sub.5, --O.sub.u2 --(C.sub.1 -C.sub.9)-heteroaryl or --S.sub.u2 -(C.sub.1 -C.sub.9)-heteroaryl; -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-perfluoroalkyl; or CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w NR(21)R(22), NR(18)R(19) and (C.sub.1 -C.sub.9)-heteroaryl; --C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl or methoxy; or --CH--CH.dbd.CH--CH--, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w2 NR(24)R(25) and NR(26)R(27); -C.sub.4)-perfluoroalkyl; times at most;

14. The method as claimed in any of claims 1, 2-12, wherein the Na.sup.+ /H.sup.+  exchange inhibitor is selected from the group consisting of e, selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or group can be replaced by O, S, NH, N--CH.sub.3 or N-benzyl; R(12)R(13)N--SO.sub.2 --; as a substituent, where phenyl is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or one of the two radicals R(2) or R(4) is hydrogen or is defined as R(1); thereof; ##STR124## in which: R(1) or R(2) is an amino group --NR(3)R(4); C.sub.3 -C.sub.7 -cycloalkyl; or or one to two substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -methylene chain, where one --CH.sub.2 -member of the methylene chain can be replaced by oxygen, S or NR(5); the other substituent R(1) or R(2) in each case is H, F, Cl, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, CF.sub.3, C.sub.m F.sub.2m+1 --CH.sub.2 --, benzyl or phenoxy, substituents selected from the group consisting of methyl, methoxy, fluorine and chlorine; or a pharmaceutically tolerable salt thereof; ##STR125## in which: R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or or group can be replaced by an O, S, NH, N--CH.sub.3 or N-benzyl; --CR(13).dbd.CHR(12) or --C.ident.CR(1 2); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(1 5); or substituted as phenyl, or 1-3 OH, or or -C.sub.8)-cycloalkyl-(C.sub.1 -C.sub.4)-alkyl, phenyl, C.sub.6 H.sub.5 --(C.sub.1 -C.sub.4)-alkyl, naphthyl, biphenylyl, 1,1-diphenyl-(C.sub.1 -C.sub.4)-alkyl, cyclopentadienyl, pyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indazolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl or cinnolinyl; are unsubstituted or substituted by 1-3 substituents from the groups F, Cl, CF.sub.3, (C.sub.1 -C.sub.4)-alkyl or -alkoxy, or NR(10)R(11) with R(10) and R(11) being H or (C.sub.1 -C.sub.4)-alkyl; or a pharmaceutically tolerable salt thereof; ##STR126## in which: R(1) or R(2) is R(3)--S(O).sub.n -- or R(4)R(5)N--SO.sub.2 -- the other substituent R(1) or R(2) in each case is H, OH, F, Cl, Br, I, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, benzyloxy or phenoxy, which is unsubstituted or carries one to three substituents selected from the group consisting of fluorine, chlorine, methyl, methoxy, hydroxyl or benzyloxy, cyclopentylmethyl, cyclohexylmethyl or phenyl, which is unsubstituted or carries one to three substituents selected from the group consisting of fluorine, chlorine, methyl and methoxy; or or selected from the group consisting of fluorine, chlorine, methyl and methoxy; or -chain, where the chain can additionally be interrupted by O, S or NR(6), R(6) is H or methyl; or a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; or a pharmaceutically tolerable salt thereof; ##STR127## in which: R(1) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring; where the rings are unsubstituted or substituted by 1-3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, trifluoromethyl, substituted by 1-3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl, halogen, nitro, amino, alkyl, sulfonamide, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, benzyloxy, hydroxyl; aminoalkyl or an aryl or a heteroaryl ring; which rings are unsubstituted or substituted by 1-3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl; in which substituents each alkyl chain or alkenyl chain can be interrupted by oxygen, sulfur or NR(8); aminoalkyl or an aryl or heteroaryl ring, which rings are unsubstituted or substituted by 1-3 groups selected from the group consisting of halogen, nitro, amino, mono(lower alkyl)amino, di(lower alkyl)amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxyl and trifluoromethyl; or a pharmaceutically acceptable salt thereof; ##STR128## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.ident.N, --CF.sub.3, R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; --[CR(12)R(13)OR(13')], --{C--[CH.sub.2 --OR(13')]R(12) (R(13)} or --[CR(18)R(17)].sub.p --(CO)--[CR(19)R(20)].sub.q --R(14); --(CH.sub.2).sub.p --(CHOH).sub.q --(CH.sub.2).sub.r --(CHOH).sub.t --R(21) or --(CH.sub.2).sub.p --O--(CH.sub.2 --CH.sub.2 O).sub.q --R(21), R(21) is hydrogen, methyl, -C.sub.6)-alkyl or, together with the carbon atom carrying them, are a (C.sub.3 -C.sub.8)-cycloalkyl, --C.sub.a H.sub.2a --R(15); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or substituted as phenyl, or 1-3 OH; --C.sub.3)-alkyl; or or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or a pharmaceutically tolerable salt thereof; ##STR129## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.ident.N, R(16)--C.sub.p H.sub.2p --O.sub.q, R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --; --C.sub.n H.sub.2n --R(7) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; --C.sub.b H.sub.2b --R(15); or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); or a pharmaceutically tolerable salt thereof; ##STR130## in which: one of the substituents R(1), R(2), R(3) or R(4): is an amino group ##STR131## R(5) is hydrogen or C.sub.(1-6) -alkyl; n is zero, 1, 2, 3 or 4; in which one CH.sub.2 group can be replaced by 1 sulfur atom or a group NR(7); or carries 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, methyl, methoxy, --NR(8)R(9); or ring, in which 1 carbon atom can be replaced by oxygen, S or NR(10); and the other substituents R(1), R(2), R(3), R(4) in each case are: F.sub.2m+1 --CH.sub.2 --O-- or R(11)-- C.sub.q H.sub.2q --X.sub.p --; which is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH.sub.3, CH.sub.3 --O-- and NR(13)R(14); or a pharmaceutically tolerable salt thereof; ##STR132## in which R(1) is R(4)R(5)N--C(X)--; (C.sub.3 -C.sub.6)-alkenyl or --C.sub.n H.sub.2n --R(7); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; (C.sub.3 -C.sub.8)-cycloalkyl, (C.sub.3 -C.sub.8)-cycloalkyl-(C.sub.1 -C.sub.4)-alkyl, phenyl, C.sub.6 H.sub.5 -(C.sub.1 --C.sub.4)-alkyl, naphthyl, biphenylyl, 1,1-diphenyl-(C.sub.1 -C.sub.4)-alkyl, cyclopentadienyl, pyridyl, thiopyridyl, pyrrolyl, furanyl, thienyl, thiazolyl, oxazolyl, indenyl, quinolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl or --W--R(8); cyclohexylmethyl, cyclopentylmethyl, --(CH.sub.2).sub.m C.sub.p F.sub.2p+1 or --C.sub.q H.sub.2q --R(10); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(11)R(12); or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; for R(2), or a pharmaceutically acceptable salt thereof; ##STR133## in which: R(1), R(2), R(3) one of the substituents R(1), R(2) or R(3) is N.sub.3, CN, OH or (C.sub.1 -C.sub.10)-alkyloxy, if at least one of the remaining substituents R(1), R(2) or R(3) is a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms; or one of the substituents R(1), R(2) or R(3) is R(4)--C.sub.n H.sub.2n --O.sub.m --; or isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted by a substituent selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(5)R(6); or one of the substituents R(1), R(2) or R(3) is --C.ident.CR(5) or --C[R(6)]=CR(5); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, hydroxyl, amino, methylamino and dimethylamino, (C.sub.1 -C.sub.9)-heteroaryl, or 1-3 OH; or or a pharmacologically acceptable salt thereof; ##STR134## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.ident.N, X.sub.o --(CH.sub.2).sub.p --(CF.sub.2).sub.q --CF.sub.3, R(5)--SO.sub.m, --C.sub.n H.sub.2n --R(8) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; ##STR135## Y is oxygen, --S-- or --NR(12)--; R(11) and R(12) are hydrogen or (C.sub.1 -C.sub.3)-alkyl; but where h, i and k are not simultaneously zero, --C.sub.b H.sub.2b --R(.sup.15); together are 4 or 5 methylene groups, where one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or a pharmaceutically tolerable salt thereof; ##STR136## in which: R(1) is R(6)--CO or R(7)R(8)N--CO; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(9); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(10)R(11); -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H2n--R(12); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n R(15); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); -C.sub.4)-perfluoroalkyl; or is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or (C.sub.3 -C.sub.8)-alkenyl, --C.sub.n H.sub.2n --R(24), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl, --C.sub.n H.sub.2n --R(29); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(30)R(31); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or (CH.sub.2).sub.b C.sub.d F.sub.2d+1, --C.sub.n H.sub.2n --R(36), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(37)R(38); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure; or --C[R(42)R(43)OH], --C.ident.CR(45), --CR(46).dbd.CHR(45), --[CR(47)R(48)].sub.u,--(CO)--[CR(49)R(50)].sub.v,--R(44); --(CHOH).sub.q --(CH.sub.2).sub.r --(CHOH).sub.t --R(51) or --(CH.sub.2).sub.p --O--(CH.sub.2 --CH.sub.2 O).sub.q --R(51); -C.sub.6)-alkyl; or -C.sub.8)-cycloalkyl; --C.sub.e H.sub.2e --R(45); from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53) where -C.sub.9)-heteroaryl, which is unsubstituted or substituted as phenyl; or 1-3 OH; or (C.sub.3 -C.sub.6)-alkenyl or --C.sub.f H.sub.2f --R(59); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; R(2); or a pharmaceutically tolerable salt thereof; ##STR137## in which: R(1) is hydrogen, F, Cl, Br, I, --NO.sub.2, --C.ident.N, --X.sub.o --(CH.sub.2).sub.p --(CF.sub.2).sub.q --CF.sub.3, R(5)--SO.sub.m --, --C.sub.n H.sub.2n --R(8) or CF.sub.3 ; is substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; ##STR138## R(11) is (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl; or --C.sub.b H.sub.2b --R(15); or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); or a pharmaceutically tolerable salt thereof; ##STR139## in which: X is N or CR(6); or the substituents R(1) to R(6) is a --CO--N.dbd.C(NH.sub.2).sub.2 group; or (C.sub.1 -C.sub.6)-alkyl; (C.sub.1 -C.sub.4)-alkyloxy or CF.sub.3 ; branched and where one carbon atom can be replaced by an oxygen or sulfur atom or by a nitrogen atom; -C.sub.10)-cycloalkyl, which is unsubstituted or substituted by 1 to 4 methyl groups or an OH group, or can contain an ethylene group --CH.dbd.CH--, and in which one methylene group can be replaced by an oxygen or sulfur atom or by a nitrogen atom; or substituents selected from the group consisting of F, Cl, Br, I, CF.sub.3, CH.sub.3 --S(O)S-- or R(9)--W.sub.y --; or or or or or R(8)--C.sub.n H.sub.2n --; or a pharmaceutically tolerable salt thereof; ##STR140## in which: R(1), R(3) or R(4) is --NR(6) C.dbd.X NR(7)R(8); -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(9); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(10 )R(11); -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.o H.sub.2o --R(12); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; the remaining substituents R(2), R(3), R(4), R(5) or R(1), R(2), R(4), R(5) or R(1), R(2), R(3), R(5) in each case (C.sub.1 -C.sub.8)-alkyl, --O.sub.tb (C.sub.3 -C.sub.8)-alkenyl, --O.sub.tc (CH.sub.2).sub.b C.sub.d F.sub.2d+1, --O.sub.td C.sub.p H.sub.2p R(18), or up to 2 groups CN, NO.sub.2, NR(16)R(17), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(19)R(20); -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, --C.sub.q H.sub.2q --R(21), where the aromatics are not substituted or are substituted by 1-3 substituents from the group F, Cl, CF.sub.3, methyl, methoxy or NR(22)R(23), R(22) and R(23) are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C1-C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, --C.sub.r H.sub.2r --R(24); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or a pharmaceutically tolerable salt thereof; ##STR141## in which: X(1) and X(2) are ##STR142## T1 is zero, 1, 2, 3 or 4; R(A) and R(B) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(106), (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.zk (CH.sub.2).sub.z1 C.sub.zm F.sub.2zm+1, NR(107)R(108), phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(109)R(110); -C.sub.4)-perfluoroalkyl; -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(111)R(112); -C.sub.4)-perfluoroalkyl; or CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or ##STR143## T2a and T2b independently of one another are zero, 1 or 2; where the double bond can have the (E)-- or (Z)-configuration; or ##STR144## T3 is zero, 1 or 2; U, YY and Z independently of one another are C or N, where U, YY, Z can carry the following number of substituents: Bonded in the ring to Number of permitted U, YY or Z a double bond substituents ______________________________________ C          yes           1 C no 2 N yes 0 N no 1 ______________________________________ -C.sub.8)-perfluoroalkyl, R(U1), R(U2), R(Y1), R(Y2), R(Z1), R(Z2) independently of one another are hydrogen, F, Cl, Br, I, CN, OR(114), (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.zka (CH.sub.2).sub.zla C.sub.zma F.sub.2zma+1, NR(115)R(116), phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, NR(117)R(118), R(117) and R(118) are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl, -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(119)R(120); -C.sub.4)-perfluoroalkyl; or CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; but where the constitution of U is nitrogen (N), YY is nitrogen (N) and Z is carbon (C) is excluded, hydrogen, F, Cl, Br, I, --C.ident.N, X.sub.zoa --(CH.sub.2).sub.zpa --(C.sub.zqa F.sub.2zqa+1), R(110a)--SO.sub.zbm, R(110b)R(1110c)N--CO, R(111a)--CO-- or R(112a)R(113a)N--SO.sub.2 --, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-alkenyl, --C.sub.zn H.sub.2zn --R(115a) or (C.sub.1 -C.sub.8)-perfluoroalkyl; where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(116a)R(117a); (C.sub.1 -C.sub.4)-alkyl; or -C.sub.4)-perfluoroalkyl or (C.sub.1 -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or (C.sub.1 -C.sub.8)-alkyl, --C.sub.za1 H.sub.2za1 R(118a) or (C.sub.3 -C.sub.8)-alkenyl, where the aromatics are not substituted or are substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(119a)R(119b); -C.sub.4)-perfluoroalkyl; or (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --C.ident.C--R(193); substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(194)R(195); or --Y--para--C.sub.6 H.sub.4 --(CO).sub.zh --(CHOH).sub.zi --(CH.sub.2).sub.zj --(CHOH).sub.zk --R(123), --Y--meta--C.sub.6 H.sub.4 --(CO).sub.zad --(CHOH).sub.zae --(CH.sub.2).sub.zaf --(CHOH).sub.zag --R(124) or --(CH.sub.2).sub.zap --(CHOH).sub.zak --R(125); or 4; but where in each case -C.sub.3)-alkyl; or SR(129), --OR(130), --NR(131)R(132) or --CR(133)R(134)R(135); --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; R(129) or are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or --W--para--(C.sub.6 H.sub.4)--R(196), --W--meta--(C.sub.6 H.sub.4)--R(197) or --W--ortho--(C.sub.6 H.sub.4)--R(198); which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino and benzyl; or R(146)X(1a)--; (CH.sub.2).sub.zbz C.sub.zdz F.sub.2zdz+1 or --C.sub.zxa H.sub.2zxa --R(151); where the aromatics are not substituted or are substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(152)R(153); -C.sub.4)-perfluoroalkyl; -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-perfluoroalkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; where A and N(*) are bonded to the phenyl nucleus of the alkanoyl parent structure; or --SR(164), --OR(165), --NHR(166), --NR(167)R(168), --CHR(169)R(170), --CR(154)R(155)OH, --C.ident.CR(156), --CR(158).dbd.CR(157) or --[CR(159)R(160)].sub.zu --(C.dbd.O)--[CR(161)R(162)].sub.zv --R(163); --(CH.sub.2).sub.zy --(CHOH).sub.zz --(CH.sub.2).sub.zaa --(CHOH).sub.zt --R(171) or --(CH.sub.2).sub.zab --O--(CH.sub.2 --CH.sub.2 O).sub.zac --R(172); (C.sub.1 -C.sub.6)-alkyl, or carrying them are a (C.sub.3 -C.sub.8)-cycloalkyl; --C.sub.8)-cycloalkyl or --C.sub.zeb H.sub.2zeb --R(173); or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(174)R(175); or which is unsubstituted or substituted as phenyl; or R(176)--NH--SO.sub.2 --; -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.zfa H.sub.2zfa --R(180); or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy or (C.sub.1 -C.sub.4)-alkyl; or CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or NR(184a)R(185), OR(184b), SR(184c) or --C.sub.znx H.sub.2znx --R(184d); substituted or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(116k)R(117k); hydrogen, (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl or (CH.sub.2).sub.zao --R(184g); or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and N R(184u) R(184v); or R(184a) and R(185) together are 4 or 5 methylene groups, of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or a pharmaceutically tolerable salt thereof; ##STR145## in which: R(1) is H, F, Cl, Br, I, CN, NO.sub.2, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ; where the aromatics are not substituted or are substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); or -C.sub.9)-heteroaryl or phenyl, substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; or latter linked via C or N, and which are unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --C[R(15)R(16)]OH, --C.ident.CR(18), --C[R(19)].dbd.CR(18), --[CR(20)R(21)].sub.k --(CO)--[CR(22)R(23)R(24)], --(CHOH).sub.h --(CH.sub.2).sub.i --(CHOH).sub.j --R(17), R(17) is hydrogen or methyl; -C.sub.6)-alkyl or together with the carbon atom carrying them are a (C.sub.3 -C.sub.8)-cycloalkyl; substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); or substituted as phenyl; or 1 to 3 OH; or --C.sub.m H.sub.2m --R(18); --(CF.sub.2).sub.o --CF.sub.3 ; or a pharmaceutically tolerable salt thereof; ##STR146## in which: X is carbonyl, sulfonyl, hydroxyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl, which is unsubstituted or substituted by 1-3 substituents from the group F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino or dimethylamino, thereof; perfluoroalkyl groups, of the formula ##STR147## in which: R(A) is hydrogen, F, Cl, Br, I, CN, OR(6), (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1 or NR(7)R(8); (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoroalkyl; --O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+1, F, Cl, Br, I or CN; but with the condition that at least one of the substituents R(1I), R(2), R(3), R(4), R(5), R(A) and R(B) is an --O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+i or an O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1 group, or a pharmaceutically tolerable salt thereof; ##STR148## in which: HA is SO.sub.m, O or NR(5); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(82)R(83); or which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; one of the two substituents R(1) and R(2) is --CO--N.dbd.C(NH.sub.2).sub.2 ; and the other in each case is hydrogen, F, Cl, Br, I, (C.sub.1 -C.sub.3)-alkyl, --OR(6), C.sub.r F.sub.2r+1, --CO--N.dbd.C(NH.sub.2).sub.2 or --NR(6)R(7); --C.ident.N, X--(CH.sub.2).sub.p --(C.sub.q --F.sub.2q+1), R(.sup.8)--SO.sub.bm, R(9)R(10)N--CO, R(11)--CO-- or R(12)R(13)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched, (C.sub.3 -C.sub.6)-alkenyl, --C.sub.n H.sub.2n --R(15), CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(16)R(17); or or of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, or --C.sub.a1 H.sub.2a1 R(18); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(19)R(20); or -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or ##STR149## Y is oxygen, --S-- or --NR(22)--; h, ad, ah independently are zero or 1; where in each case -C.sub.3)-alkyl; or (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.9 H.sub.2g R(26); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); -C.sub.4)-pefluoroalkyl; or --NR(31)R(32) or --CR(33)R(34)R(35); --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or ##STR150## R(96), R(97) and R(98) independently are (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl; or R(38)R(39)N--SO.sub.2 --; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.s H.sub.2s R(40); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(41)R(42); -C.sub.4)-perfluoroalkyl; (C.sub.3 --C.sub.8)-alkenyl or --C.sub.w H.sub.2w w--R(43); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(44)R(45); --C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or (CH.sub.2).sub.b C.sub.d F.sub.2d+1 or --C.sub.x H.sub.2x --R(51); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53); -C.sub.4)-perfluoroalkyl; or (C.sub.1 -C.sub.4)-perfluoroalkyl; or of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, where A and N(*) are bonded to the phenyl nucleus of the benzoylguanidine parent structure; or --NHR(66), --NR(67) R(68), --CH R(69)R(70), --C(OH)R(54)R(55), --C.ident.CR(56), --CR(58).dbd.CH R(57), --[CR(59) R(60)].sub.u --(CO)--[CR(61) R(62)].sub.v --R(63); R(64), R(65), R(66), R(67) and R(69) --(CH.sub.2).sub.aa --(CH.sub.2 OH).sub.t --R(71) or --(CH.sub.2).sub.ab --O--(CH.sub.2 --CH.sub.2 O).sub.ac --R(72), R(71) and R(72) are hydrogen or methyl; (C.sub.1 -C.sub.6)-alkyl; or them are a (C.sub.3 -C.sub.8)--cycloalkyl; --C.sub.e H.sub.2e --R(73); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(74)R(75); or which is unsubstituted or substitued as phenyl; or (C.sub.3 -C.sub.6)-alkenyl, -C.sub.f H.sub.2f --R(80); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, R(79) or -C.sub.4)-alkyl, or together are 4 or 5 methylene groups, N-benzyl; or of which one or two CH.sub.2 groups can be replaced by CH--C.sub.dm H.sub.2dm+1, or a pharmaceutically tolerable salt thereof; ##STR151## in which: T, U, V, W, X, Y and Z independently of one another are nitrogen or carbon; but with the restriction that X and Z are not simultaneously nitrogen, and that T, U, V, W, X, Y and Z carry no substituents if they are nitrogen, and that no more thai four of them are simultaneously nitrogen, (C.sub.1 -C.sub.3)-alkyl, (C.sub.1 -C.sub.3)-perfluoroalkyl, OR(8), NR(8)R(9) or C(.dbd.O)N.dbd.C(NH.sub.2).sub.2 ; -C.sub.3)-alkyl, or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; F, Cl, Br, I, --C.ident.N, X.sub.k --(CH.sub.2).sub.p --(C.sub.q F.sub.2q+1), R(10a)--SO.sub.bm, R(10b)R(10c)N--CO, R(11)--CO-- or R(12)R(13)N--SO.sub.2 --, -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl, --C.sub.n H.sub.2n --R(15) or (C.sub.1 -C.sub.8)-perfluoroalkyl; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); or or of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or -C.sub.8)-alkyl, --C.sub.a1 H.sub.2al R(18) or (C.sub.3 -C.sub.8)--alkenyl; where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(19a)R(19b); -C.sub.4)-perfluoroalkyl; or -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino or dimethylamino; or ##STR152## Y is oxygen, --S-- or --NR(22)--; h, ad, ah independently of one another are zero or 1; 1, 2, 3 or 4; but where in each case (C.sub.1 -C.sub.3)-alkyl; or --OR(30), --NR(31)R(32) or --CR(33)R(34)R(35); H.sub.2a --(C.sub.1 -C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; are hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or ##STR153## R(96), R(97) and R(98) independently of one another are (C.sub.1 -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstitued or substituted by 1 to 3 substituents from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino or benzyl; or R(46)X(1)--; (CH.sub.2).sub.b C.sub.d F.sub.2d+1 or --C.sub.x H.sub.2x --R(51); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53); -C.sub.4)-perfluoroalkyl; or (C.sub.1 -C.sub.4)-perfluoroalkyl; or of which one CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; where A and N(*) are bonded to the phenyl nucleus of the heteroaroylguanidine parent structure; or --OR(65), --NHR(66), --NR(67)R(68), --CH R(69)R(70) or --CR(54)R(55)OH, --C.ident.CR(56), --CR(58).dbd.CR(57) or --[CR(59)R(60)].sub.u,--CO--[CR(61)R(62)].sub.v --R(63); R(64), R(65), R(66), R(67) and R(69) --(CH.sub.2).sub.aa --(CHOH).sub.t --R(71) or --(CH.sub.2).sub.ab --O--(CH.sub.2 --CH.sub.2 O).sub.ac --R(72); (C.sub.1 -C.sub.6)-alkyl; or them are (C.sub.3 -C.sub.8)-cycloalkyl; or --C.sub.e H.sub.2e --R(73); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(74)R(75); or which is unsubstituted or substituted as phenyl; or R(76)--NH--SO.sub.2 --; -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.f H.sub.2f R(80); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; or NR(84a)R(85), OR(84b), SR(84c) or --C.sub.n H.sub.2n --R(84d); or is substituted by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl or (CH.sub.2).sub.ax --R(84g); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(84u)R(84v); or CH.sub.2 group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl, or a pharmaceutically tolerable salt thereof; ##STR154## in which: R(1) is R(6)--SO.sub.m ; straight-chain or branched; alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, group consisting of F, Cl, methyl and methoxy; or pyrrol-3-yl, which is not substituted or is substituted by 1 to 4 substituents selected from the group consisting of F, Cl, Br, I, CN, alkanoyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxycarbonyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, formyl, carboxyl, CF.sub.3, methyl and methoxy; or 3 carbon atoms, F, Cl, Br, I, CN, OR(7), NR(8)R(9) or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms; or a pharmacologically acceptable salt thereof; perfluoroalkyl groups, of the formula ##STR155## in which: R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C.sub.1 -C.sub.8)-alkyl, O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, (C.sub.3 -C.sub.8)-cycloalkyl or NR(7)R(8); (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl; substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoroalkyl; or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; O.sub.p (CH.sub.2).sub.f C.sub.g F.sub.2g+1 or (C.sub.3 -C.sub.8)-cycloalkyl; (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl; by 1-3 substituents from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; C.sub.e F.sub.2e+1, (C.sub.3 -C.sub.8)-cycloalkyl, F, Cl, Br, I or CN; but with the condition that at least one of the substituents R(A), R(B), R(C), R(D), R(1), R(2), R(4) or R(5) is an O.sub.r (CH.sub.2).sub.a C.sub.b F.sub.2b+1, O.sub.p (CH.sub.2).sub.f C.sub.g F.sub.2g+1 or O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+1 group and R(3) is not an O.sub.t (CH.sub.2).sub.d C.sub.e F.sub.2e+ 1 group; or a pharmaceutically tolerable salt thereof; ##STR156## in which: R(1) is NR(50)R(6), R(50) and R(6) independently of one another are hydrogen, (C.sub.1 -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-perfluoroalkyl; --, R(11)R(12)N--CO--, R(13)--CO-- or R(14)R(15)N--SO.sub.2 --; are (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 --C.sub.6)-alkenyl or --C.sub.ab H.sub.2ab --R(16); is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy or NR(17)R(18); -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or or --OR(22), --NR(23)R(24) or --CR(25)R(26)R(27); H.sub.2b --(C.sub.1 --C.sub.9)-heteroaryl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or Br, I, CN, --(Xa).sub.dg --C.sub.da H.sub.2da+1, --(Xb).sub.dh --(CH.sub.2).sub.db --C.sub.de F.sub.2de+1, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.df H.sub.2df R(30); where the aromatics phenyl, biphenylyl or naphthyl are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(31)R(32); -C.sub.4)-perfluoroalkyl; or --(Xe)--(CH.sub.2).sub.eb R(45); -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl or (CH.sub.2).sub.e --R(42); is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(43)R(44); -C.sub.4)-alkyl; or group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, NR(50)R(51) and --(Xfa)--(CH.sub.2).sub.ed --(Xfb)R(46); (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; where R(3) and R(4), however, cannot be hydrogen, or a pharmaceutically tolerable salt thereof; ##STR157## in which: one of the three substituents R(1), R(2) and R(3) is (C.sub.1 -C.sub.9)-heteroaryl-N-oxide, substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or --NR(10)R(11) or --CR(10)R(11)R(12); is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; and the other substituents R(1), R(2) and R(3) in each case independently of one another are (C.sub.1 -C.sub.8)-alkyl, (C.sub.2 -C.sub.8)-alkenyl or --C.sub.m H.sub.2m R(14); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(15)R(16), R(15) and R(16) or one another are hydrogen, F, Cl, Br, I, --C.ident.N, X--(CH.sub.2).sub.p --(C.sub.q F.sub.2q+1), R(22)--SO.sub.u, R(23)R(24)N--CO, R(25)--CO-- or R(26)R(27)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched; (C.sub.2 -C.sub.6)-alkenyl, --C.sub.n H.sub.2n --R(29) or CF.sub.3 ; or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(30)R(31); or -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; or one another are OR(35) or NR(35)R(36); R(35) and R(36) or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, -C.sub.4)-alkyl, F, Cl, --OR(32), --NR(33)R(34) or C.sub.r F.sub.2r+1 ; (C.sub.1 -C.sub.3)-alkyl; or a pharmaceutically tolerable salt thereof; ##STR158## in which: R(1) is hydrogen, F, Cl, Br, I, CN, NO.sub.2, OH, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl, O.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ; or (C.sub.3 -C.sub.6)-alkenyl, CF.sub.3 or --C.sub.n H.sub.2n --R(8); or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-alkyl; or CH.sub.2 group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl, or -C.sub.9)-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl; or latter linked via C or N, the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; --CF.sub.3)][R(15)], --C[(CF.sub.2).sub.r --CF.sub.3 ].dbd.CR(15)R(16); -C.sub.4)-alkyl; --(CH.sub.2).sub.s --(CF.sub.2).sub.t --CF.sub.3 ; or a pharmaceutically tolerable salt thereof; ##STR159## in which: one of the three substituents R(1), R(2) and R(3) is --Y--4--[(CH.sub.2).sub.k --CHR(7)--(C.dbd.O)R(8)]-phenyl, --Y--3--(CH.sub.2).sub.k --CHR(7)--(C.dbd.O)R(8)]-phenyl or --Y--2--[(CH.sub.2).sub.k --CHR(7)--(C.dbd.O)R(8)]--phenyl, substituents from the group F, Cl, --CF.sub.3, methyl, hydroxyl, methoxy, or --NR(37)R(38); -C.sub.8)-alkyl, --(C.sub.1 -C.sub.8)-alkanoyl, --(C.sub.1 -C.sub.8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl; or -C.sub.8)-alkyl or benzyl; and the other radicals R(1), R(2) and R(3) in each case -C.sub.8)-alkenyl or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); or another are R(18)R(19)N--(C.dbd.Y')--NH--SO.sub.2 --; -C.sub.8)-alkyl, --(C.sub.3 -C.sub.6)--alkenyl or --(CH.sub.2).sub.t --R(21); or substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methoxy and --(C.sub.1 -C.sub.4)-alkyl; or group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N--benzyl; or another are hydrogen, F, Cl, Br, 1, --C.ident.N, X--(CH.sub.2).sub.p --(C.sub.q F.sub.2q+1), R(22)--SO.sub.u --, R(23)R(24)N--CO--, R(25)--CO-- or R(26)R(27)N--SO.sub.2 --, where the perfluoroalkyl group is straight-chain or branched; -C.sub.8)-alkyl, --(C.sub.3 -C.sub.6)-alkenyl, --(CH.sub.2).sub.n --R(29) or --CF.sub.3 ; substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(30)R(31); or -C.sub.4)-alkyl; or groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N-benzyl; or another are --OR(35) or --NR(35)R(36); -C.sub.6)-alkyl; or group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N--benzyl; -C.sub.4)-alkyl, F, Cl, --OR(32), --NR(33)R(34) or --C.sub.r F.sub.2r+ 1; --(C.sub.1 -C3)-alkyl; or a pharmaceutically tolerable salt thereof; ##STR160## in which: R(1) is R(6)--CO or R(7)R(8)N--CO; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(9), where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(10)R(11), -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n --R(12); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)--perfluoroalkyl; or group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; -C.sub.8)-alkyl, (C.sub.1 -C.sub.8)-perfluoroalkyl, (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n R(15); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(16)R(17); -C.sub.4)-perfluoroalkyl; or is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino, dimethylamino; hydrogen, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n -- where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); -C.sub.4)-perfluoroalkyl; (C.sub.3 -C.sub.8)-alkenyl or --C.sub.n H.sub.2n -- R(29); where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(30)R(31); -C.sub.4)-perfluoroalkyl; -C.sub.4)-perfluoroalkyl; group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; (CH.sub.2).sub.b C.sub.d F.sub.2d+1 or --C.sub.n H.sub.2n -- where the aromatics are not substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(37)R(38); -C.sub.4)-perfluoroalkyl; -C.sub.4)-perfluoroalkyl; group can be replaced by oxygen, S, NH, N-CH.sub.3 or N-benzyl; benzoylguanidine parent structure; --CR(42)R(43)OH, --C=CR(45), --CR(46)=CR(45) or --[CR(47)R(48)].sub.u --CO--[C(R49)R(50)].sub.v -R(44); --(CHOH).sub.q --(CH.sub.2).sub.r --(CHOH).sub.t -- R(51) or --(CH.sub.2).sub.p --O--(CH.sub.2 --CH.sub.2 O).sub.q --R(51); -C.sub.6)-alkyl; -C.sub.8)-cycloalkyl; --C.sub.e H.sub.2e -R(45); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(52)R(53); substituted as phenyl; 1-3 OH; hydrogen or methyl; -C.sub.8)-alkyl, (C.sub.3 -C.sub.6)-alkenyl or --C.sub.f H.sub.2f -R(59); substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methoxy and (C.sub.1 -C.sub.4)-alkyl; group can be replaced by oxygen, S, NH, N-CH.sub.3 or N-benzyl; R(2), but where at least one of the substituents R(2), R(3), R(4) and R(5) must be OH; or a pharmaceutically tolerable salt thereof; ##STR161## in which: one of the three substituents R(1), R(2) and R(3) is R(6)-A-B-D-; amidino group R(7)R(8)N-C[=N-R(9)]- or a guanidino group ##STR162## R(7), R(8), R(9) and R(10) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; replaced by a heteroatom group O, SO.sub.m or NR(11), H.sub.2a ; replaced by a heteroatom group O, SO.sub.m or NR(11); one or two methylene groups can be replaced by one of the groupings selected from the group consisting of --O--, --CO--, --CH[OR(20)]--, --SO.sub.m --, --NR(20)--, --NR(20)--CO--, --NR(20)--CO--NH--, --NR(20)--CO--NH--SO.sub.2 -- ##STR163## and --SO.sub.aa [NR(19)].sub.bb--; and where in the group C.sub.b H.sub.2b a methylene group can be replaced by --CH--R(99), where R(99) together with R(7) forms a pyrrolidine or piperidine ring; ##STR164## R(12) and R(13) independently of one another are hydrogen, methyl, F, Cl, Br, I, CF.sub.3 or --SO.sub.w -R(14); 1, 2, 3 or 4 carbon atoms; independently of one another are hydrogen, F, Cl, Br, I, --CN, --(C.sub.1 -C.sub.8)-- alkyl, --(C.sub.2 -C.sub.8)-alkenyl, --NR(35)R(36) or R(1.sup.7)--C.sub.g H.sub.2g --Z.sub.h --; 1, 2, 3, 4, 5 or 6 carbon atoms; group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N--benzyl; --NR(18)--CO--NH-- or --NR(18)--SO.sub.2 --; F.sub.2k+1 --; or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl and methoxy; or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, hydroxyl, methoxy, --NR(37)R(38), CH.sub.3 SO.sub.2 -- and H.sub.2 NO.sub.2 S--; R(37) and R(38) are hydrogen or --CH.sub.3 ; 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or --C.sub.r F.sub.2r+1 ; having 1, 2 or 3 carbon atoms; ##STR165## in which: R(1) and R(2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, O-alkyl having 1, 2, 3 or 4 carbon atoms, O-C(=O)-alkyl having 1, 2, 3 or 4 carbon atoms or C.sub.m H.sub.2m -NR(12)R(13); 1, 2, 3 or 4 carbon atoms; NH.sub.2, C(=O)-NH-alkyl having 1, 2, 3 or 4 carbon atoms, C(=O)-N(alkyl).sub.2 having 1, 2, 3 or 4 carbon atoms in each alkyl group, alkenyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkynyl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, alkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, alkenylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkenyl group, alkynylaryl having 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms in the alkynyl group, C.sub.1 -C.sub.4 -alkyl-substituted aryl, C.sub.1 -C.sub.4 -alkylheteroaryl, C.sub.1 -C.sub.4 -alkenylheteroaryl, aminoalkylaryl having 1, 2, 3 or 4 carbon atoms in the alkyl group, substituted aryl, heteroaryl and substituted heteroaryl; having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, O-alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, halogen, (such as F, Cl, Br, I), OH, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 0-lower alkyl, 0-aryl, 0-lower alkylaryl, O-substituted aryl, O-lower alkyl-substituted aryl, O--C(=O)--C.sub.1 -C.sub.4 -alkylaryl, O--C(=O)--NH--C.sub.1 -C.sub.4 -alkyl, O--C(=O)--N(C.sub.1 -C.sub.4 -alkyl).sub.2, NO.sub.2, CN, CF.sub.3, NH.sub.2, NH-C(=O)--C.sub.1 -C.sub.4 -alkyl, NH-C(=O)-NH.sub.2, COOH, C(=O)--O--C.sub.1 -C.sub.4 -alkyl, C(=O)--NH.sub.2, C(=O)--NH--C.sub.1 -C.sub.4 -alkyl, C(=O)-N(C.sub.1 -C.sub.4 -alkyl).sub.2, C.sub.1 -C.sub.4 --COOH, C.sub.1 -C.sub.4 -alkyl-C(=O)--O--C.sub.1 -C.sub.4 -alkyl, SO.sub.3 H, S0.sub.2 -alkyl, SO.sub.2 -alkylaryl, SO.sub.2 --N-- (alkyl).sub.2 SO.sub.2 -N(alkyl)(alkylaryl), C(=O)-R(11), C.sub.1 -C.sub.10 -alkyl-C(=O)-R(11), C.sub.2 -C.sub.10 -alkenyl-C(=O)-R(11), C.sub.2 -C.sub.10 -alkynyl-C(=O)-R(11), NH-C(=O)-C.sub.1 -C.sub.10 --alkyl-C(=O)-R(11), O--C.sub.1 -C,.sub.1 -alkyl-C(=O)-R(11); substituted aryl, NH.sub.2, NH-C.sub.1 -C.sub.4 -alkyl, N-(C.sub.1 -C.sub.4 -alkyl).sub.2, S0.sub.3 H, S0.sub.2 -alkyl, S0.sub.2 -alkylaryl, SO.sub.2 -N-(alkyl).sub.2, SO.sub.2 -N(alkyl)(alkylaryl); alkyl, cycloalkyl, aryl, alkylaryl; ring; ##STR166## in which: R(1), R(2) and R(3) independently of one another are --Y--[4-R(8)-phenylen], --Y--[3-R(8)-phenylen] or --Y--[2-R(8)-phenylen], substituents from the group consisting of F, Cl, --CF.sub.3, methyl, hydroxyl, methoxy and --NR(96)R(97); --(C.sub.1 -C.sub.8)-alkyl, benzyl, --(C.sub.2 -C.sub.8)-alkylene-NR(11)R(12), (C.sub.2 -C.sub.8)-alkylene-NR(13)-(C.sub.2 -C.sub.8)-alkylene-NR(37)R(38) or (C.sub.0 -C.sub.8)-alkylene-CR(39)R(40)CR(41)R(42)(C.sub.0 -C.sub.8)-alkylene-N R(43)R(44); another are hydrogen, --(C.sub.1 -C.sub.8)-alkyl or benzyl; --(C1-C8)-alkyl or --(C.sub.0 -C.sub.3)-alkylenephenyl, where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl and methoxy; group can be replaced by oxygen, --S--, --NH--, --N--CH.sub.3 or --N-benzyl; alkyl having 1, 2, 3 or 4 carbon atoms; pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl, methoxy; -C.sub.8)-alkyl, --(C.sub.2 -C.sub.8)-alkenyl or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); --Q-4-[(CH.sub.2).sub.k -CHR(17)-(C=O)R(20)]-phenyl, --Q--3--[(CH.sub.2).sub.k --CHR(17)-(C=O)R(20)]-phenyl or --Q--2-[(CH.sub.2).sub.k --CHR(17)-(C=O)R(20)]-phenyl, substituents from the group F, Cl, --CF.sub.3, methyl, hydroxyl, methoxy and --NR(35)R(36); -C.sub.8)-alkyl, --(C.sub.1 -C.sub.8)-alkanoyl, --(C.sub.1 -C.sub.8)-alkoxycarbonyl, benzyl, benzyloxycarbonyl; -C.sub.8)-alkyl or benzyl; -C.sub.9)-heteroaryl, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents from the group F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; --CR(25)R(26)R(27); unsubstituted or substituted by 1-3 substituents from the group F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or (C.sub.1 -C.sub.4)-alkyl, -C.sub.9)-heteroaryl-N-oxide, which is linked via C or N and which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; --NR(28)R(29) or --CR(28)R(29)R(30); is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; (C.sub.1 -C.sub.4)-alkyl; I, --C=N, T-(CH.sub.2).sub.h --(C.sub.i F.sub.2i+1), R(31)SO.sub.1 --, R(32)R(33)N--CO--, R(34)--CO-- or R(45)R(46)N-SO.sub.2, where the perfluoroalkyl group is straight-chain or branched; -C.sub.8)-alkyl, --(C.sub.3 -C.sub.6)-alkenyl, (CH.sub.2).sub.n R(48) or --CF.sub.3 ; substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(49)R(50); 1, 2, 3 or 4 carbon atoms; of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N--benzyl; an amidino group R(52)R(53)N--C[=N--R(54)]-- or a guanidino group R(52)R(53)N--C[=N--R(54)]--NR(55)--; alkyl having 1, 2, 3 or 4 carbon atoms; be replaced by a heteroatom group O, SO.sub.d or NR(56), H.sub.2y ; by a heteroatom group O, SO.sub.d or NR(56); H.sub.2e a carbon atom can be replaced by one of the groupings --O--, --CO--, --CH[OR(57)]--, --SO.sub.r --, --NR(57)--, --NR(57)--CO--, --NR(57)--CO--NH--, --NR(57)--CO--NH--SO.sub.2 -- or --NR(57)--SO.sub.2 --; ##STR167## R(58) and R(59) independently of one another are hydrogen, methyl, methoxy, F, Cl, Br, I, CF.sub.3 or --SO.sub.s --R(60); 1, 2, 3 or 4 carbon atoms; --CF[R(65)][R(66)], --CF[(CF.sub.2).sub.q --CF.sub.3)][R(65)], --C[(CF.sub.2).sub.p --CF.sub.3 ]=CR(65) R(66); 5, 6 or 7 carbon atoms; 1, 2, 3 or4 carbon atoms; --NR(67)R(68); 1, 2, 3, 4, 5 or 6 carbon atoms; CH.sub.2 group can be replaced by oxygen, --S--, SO.sub.2, --NH--, --NCH.sub.3 or --N--benzyl; 3 or 4 carbon atoms, F, Cl, --OR(69), --NR(70)R(71) or --C.sub.2 F.sub.2z+1 ; having 1, 2 or 3 carbon atoms; 2, 3 or 4 carbon atoms; the formula ##STR168## in which: R(6) is hydrogen, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or phenyl, where the phenyl group is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoroalkyl; or F; R(5) must be fluorine; ##STR169## in which: R(1) is R(4)-SO.sub.m or R(5)R(6)N--SO.sub.2 --; 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5 or 6 carbon atoms, CF.sub.3 or --C.sub.n H.sub.2n -R(7); is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(8)R(9); group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, --C.sub.s H.sub.2s --(C.sub.3 -C.sub.8)-cycloalkyl or an aromatic system selected from the group consisting of pyridyl, pyrrolyl, quinolyl, isoquinolyl, imidazolyl or phenyl; imidazolyl and phenyl are unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; ##STR170## in which: at least one of the substituents R(1), R(2), R(3), R(4) and R(5) is 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group, T, T-alkylene having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group; is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(21)R(22); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; 8 or 9 carbon atoms; 2, 3, 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; group can be replaced by oxygen, S, NH, N--CH.sub.3 or N-benzyl; substituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(27)R(28); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; independently of one another are H, F, Cl, Br, I, CN, --O.sub.n --C.sub.m H.sub.2m+1, --O.sub.p --(CH.sub.2).sub.s --C.sub.q F.sub.2q+1 or --C.sub.r H.sub.2r R(10); where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(11)R(12); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; ##STR171## in which: at least one of the substituents R(1), R(2) and R(3) is R(6)--C(OH).sub.2 --; straight-chain or branched; are hydrogen, OH, F, Cl, Br, I, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, or phenoxy, which is unsubstituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, methyl and methoxy; alkyl-SO.sub.x, --CR(7)=CR(8)R(9) or --C=CR(9); 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, which is unsubstituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl and methoxy; -C.sub.4)-alkyl, naphthyl, where phenyl, C.sub.6 H.sub.5 -(C.sub.1 -C.sub.4)-alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl and imidazolyl are unsubstituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; SR(10), --OR(10), --CR(10)R(1 1)R(12); isoquinolinyl, pyridinyl, imidazolyl or phenyl, and phenyl are unsubstituted or are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; or alkyl having 1, 2, 3 or 4 carbon atoms; or 3 carbon atoms, F, Cl, Br, I, CN, OR(13), NR(14)R(15), --(CH.sub.2).sub.n -(CF.sub.2).sub.o -CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms; ##STR172## in which: at least one of the three substituents R(1), R(2) and R(3) is a benzoylguanidine, ##STR173## which is unsubstituted or substituted in the phenyl moiety by 1-4 radicals selected from the group consisting of alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, --(CH.sub.2).sub.m -R(14), F, Cl, Br, I, --C=N, CF.sub.3, R(22)SO.sub.2 --, --NR(35)R(36); is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH.sub.2).sub.n R(29) or --CF.sub.3 ; substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy and --NR(30)R(31); R(30) and R(31) are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; 1, 2, 3 or 4 carbon atoms; groups, of which one CH.sub.2 group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N--benzyl; 1, 2, 3, 4, 5 or 6 carbon atoms; group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N-benzyl; substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy, SO.sub.2 R(5), SO.sub.2 NR(6)R(7) and --NR(32)R(33); 2, 3 or 4 carbon atoms; 1, 2, 3 or 4 carbon atoms; substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; and the other substituents R(1), R(2) and R(3) in each case independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, (CH.sub.2).sub.p R(10); substituents selected from the group consisting of F, Cl, --CF.sub.3, methyl, methoxy, --SO.sub.2 NR(17)R(8) and --SO.sub.2 R(9); 2, 3 or 4 carbon atoms; ##STR174## in which: R(1) is alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or NR(7)R(8); 2, 3, 4, 5, 6, 7 or 8 carbon atoms; --SO.sub.2 R(9); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms; ##STR175## in which: one of the radicals R(1), R(2), R(3) and R(4) is --CO--N=C(NH.sub.2).sub.2 ; and of the other radicals R(1), R(2), R(3) and R(4) in each case: --OR(32), having 1, 2, 3 or 4 carbon atoms; --CN, CF.sub.3, --CO--N=C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); pyrrol-3-yl, which is not substituted or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl, methoxy; R(23)R(24)N--CO--, R(28)--CO-- or R(29)R(30)N--SO.sub.2 ; methyl; 1, 2, 3, 4, 5 or 6 carbon atoms; group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N--benzyl; phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; X-(CH.sub.2).sub.y --CF.sub.3 or phenyl, from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(6)R(7); or a pharmaceutically tolerable salt thereof; ##STR176## in which: one of the radicals R(1), R(2), R(3) and R(5) is --CO--N=C(NH.sub.2).sub.2 ; 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms; --CO--N=C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); R(29)R(30)N--SO.sub.2 ; methyl; 1, 2, 3, 4, 5 or 6 carbon atoms; group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or-N-benzyl; phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms, --(C.sub.3 -C.sub.8)-cycloalkyl or --(CH.sub.2).sub.m R(14); from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and --NR(15)R(16); or a pharmaceutically tolerable salt thereof; as) a diaryldicarboxylic acid diguanidide of the formula ##STR177## in which: one of the radicals R(1), R(2), R(3), R(4) and R(5) is --CO--N=C(NH.sub.2).sub.2 ; are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(32), --NR(33)R(34) or CF.sub.3 ; having 1, 2, 3 or 4 carbon atoms; are hydrogen, F, Cl, Br, I, OH, --CN, CF.sub.3, --CO--N=C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.m R(14); substituted or is substituted by 1-3 substituents selected from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(15)R(16); are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C.sub.8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl, methoxy; R(23)R(24)N--CO--, R(28)--CO-- or R(29)R(30)N--SO.sub.2 ; methyl; are --OR(35) or --NR(35)R(36); 1, 2, 3, 4, 5 or 6 carbon atoms; group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N--benzyl; --NR(25)R(26), --CR(25)R(26)R(27); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; --CO--N=C(NH.sub.2).sub.2 ; are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, --OR(132), --NR(133)R(134) or CF.sub.3 ; alkyl having 1, 2, 3 or 4 carbon atoms; are hydrogen, F, Cl, Br, I, OH, --CN, CF.sub.3, --CO--N=C(NH.sub.2).sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or --(CH.sub.2).sub.mm R(114); from the group consisting of F and Cl, --CF.sub.3, methyl, methoxy and --NR(115)R(116); are pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or is substituted by 1-4 substituents selected from the group consisting of F, Cl, Br, I, --CN, (C.sub.2 -C8)-alkanoyl, (C.sub.2 -C.sub.8)-alkoxycarbonyl, formyl, carboxyl, --CF.sub.3, methyl and methoxy; R(123)R(124)N--CO--, R(128)--CO-- or R(129)R(130)N--SO.sub.2 ; or methyl; are --OR(135) or --NR(135)R(136); 1, 2, 3, 4, 5 or 6 carbon atoms; group can be replaced by oxygen, --S--, --NH--, --NCH.sub.3 or --N--benzyl; --NR(125)R(126) or --CR(125)R(126)R(127); phenyl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; --NR(17)--CO--NR(18)--SO.sub.2 --, --NR(19)--SO.sub.2 --, --SO.sub.2 --N R(19)--SO.sub.2 --, --SO.sub.2 --NR(19)--CO--, --O--CO--NR(19)--SO.sub.2 -- or --CR(20)=CR(21)--; one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms ##STR178## in which: at least one of the substituents R(1), R(2) and R(3) is --O.sub.p --(CH.sub.2).sub.s --C.sub.q F.sub.2q+1, R(40)CO-- or R(31)SO.sub.k --; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl and methoxy; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl or methoxy; atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms, group can be replaced by oxygen, S, NH, N-CH.sub.3 or N-benzyl; of one another are H, F, Cl, Br, I, CN, --O.sub.na --C.sub.ma H.sub.2ma+1 or --O.sub.ga C.sub.ra H.sub.2ra R(10); where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl and methoxy; alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(14)R(15); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; ##STR179## in which: R(2) and R(3) independently of one another are hydrogen, Cl, Br, I, (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.8)-cycloalkyl or --OR(5); -C.sub.8)-cycloalkyl; substituents R(2) and R(3) are not simultaneously hydrogen, or a pharmaceutically tolerable salt thereof; ##STR180## in which: R(1) is H, F, Cl, Br, I, CN, NO.sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ; R(6); biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); atoms; atoms in the cycloalkyl ring, or phenyl, from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino, --C[R(15)R(16)OH], --C=CR(18), --C[R(19)]=CHR(18), --C[R(20)R(21 )].sub.k --(CO)-[CR(22)R(23)].sub.1 -R(24), --(CHOH).sub.h --(CH.sub.2).sub.i --(CHOH).sub.j --R(17) or --(CH.sub.2).sub.g --O--(CH.sub.2 --CH.sub.2 O).sub.h --R(24); 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms; group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); is unsubstituted or substituted as phenyl; unsubstituted or substituted by 1-3 OH; hydrogen or methyl; 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.m H.sub.2 m--R(18); ##STR181## in which: R(1) is H, F, Cl, Br, I, CN, NO.sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ; R(.sup.6); biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); atoms; atoms in the cycloalkyl ring, or phenyl, from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; 7, 8 or 9 carbon atoms, with the latter being linked via a carbon atom or a nitrogen atom of the ring, selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino, --C[R(15)R(16)OH], --C=CR(18), --C[R(19)]=CHR(18), --C[R(20)R(21 )].sub.k --(CO)-[CR(22)R(23)].sub.1 -R(24), --(CHOH).sub.h --(CH.sub.2).sub.i -(CHOH).sub.j --R(17) or --(CH.sub.2).sub.g --O--(CH.sub.2 -CH.sub.2 O).sub.h --R(24); 3, 4, 5 or 6 carbon atoms or, together with the carbon atom carrying them, are cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms; group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); hydrogen or methyl; 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.m H.sub.2m -R(18); carbon atoms, F, Cl, Br, I or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ; ##STR182## in which: R(1), R(2) and R(3) independently of one another are R(10)--SO.sub.a -- or R (14)R(15)N--SO.sub.2 --; 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5 or 6 carbon atoms or --C.sub.ab H.sub.2ab -R(16); is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(17)R(18); alkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, sulfur, NH, N--CH.sub.3 or N-benzyl; --NR(23)R(24) or --CR(25)R(26)R(27); H.sub.2b -(C.sub.1 -C.sub.9)-heteroaryl, group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; I, CN, --(Xa).sub.dg --C.sub.da H.sub.2da+1, --(Xb).sub.dh --(CH.sub.2).sub.db --C.sub.de F.sub.2de+1, alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.df H.sub.2df R(30); having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3 or 4 carbon atoms; biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(31)R(32); perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; --(Xe)--(CH.sub.2).sub.eb R(45); 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or (CH.sub.2).sub.e --R(42); not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(43)R(44); alkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, sulfur, NH, N-CH.sub.3 or N-benzyl; having 1, 2, 3 or 4 carbon atoms; from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, NR(50)R(51) and --(Xfa)--(CH.sub.2).sub.ed --(Xfb)R(46); alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3 or 4 carbon atoms; --R(54) or --(CH.sub.2).sub.g --O--(CH.sub.2 --CH.sub.2 O).sub.h --R(54); 2, 3 or 4 carbon atoms; carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, OH, F, Cl, Br, I, CN, --O.sub.n --(CH.sub.2).sub.o --(CF.sub.2).sub.p --CF.sub.3 ; ##STR183## in which: R2, R3, R4, R5, R6, R7 and R8 independently of one another are H, F, Cl, Br, I, CN, NO.sub.2, CF.sub.3, C.sub.2 F.sub.5 or X.sub.a Y.sub.b Z; SO.sub.2 NR(10), OC=O, NR(10)C=O or NR(10)SO.sub.2, the left atom; 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; p- or m-phenylene; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; 3, 4, 5, 6 or 7 carbon atoms, C(=O)R(15), SO.sub.2 R(15), NR(16)R(17) or phenyl, from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(21)R(22); atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; or OR(20); 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; N-benzyl or N-(p-chlorophenyl); having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, S, NH, N--CH.sub.3, N-benzyl or N-(p-chlorophenyl); atoms, substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(21)R(22); substituents R(2), R(3), R(5), R(6), R(7) and R(8) is not hydrogen; ##STR184## in which: at least one of the substituents R1, R3, R4, R5, R6, R7 and R8 is 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; these CH.sub.2 groups can be replaced by O, S, NR(13) or o-, p- or m-phenylene; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; heteroatom of the group XY.sub.a --alternatively O or NR(14); R(14) is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; NR(16)R(17); OR(20); 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, S, NH, N--CH.sub.3, N-benzyl or N-(p-chlorophenyl); having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, S, NH, N-CH.sub.3, N-benzyl or N-(p-chlorophenyl); NR(30)C=O or NR(30)SO.sub.2, the left atom; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; 3, 4, 5, 6, 7, 8 or 9 carbon atoms, substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(21)R(22); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; OR(20); 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, S, NH, N-CH.sub.3, N-benzyl or N-(p-chlorophenyl); having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, S, NH, N-CH.sub.3, N-benzyl or N-(p-chlorophenyl); which are still not allocated by the definitions given above, independently of one another are H, F, Cl, Br, I, CN, NO.sub.2, CF.sub.3, C.sub.2 F.sub.5 or V.sub.p Q.sub.q U; CR(66)R(67); 2, 3, 4, 5 or 6 carbon atoms, perfluoroalkyl having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5, 6 or 7 carbon atoms; p- or m-phenylene; having 1, 2, 3 or 4 carbon atoms or cycloalkyl having 3, 4, 5 or 6 carbon atoms; 3, 4, 5, 6 or 7 carbon atoms, C(=O)R(65), SO.sub.2 R(65), NR(61)R(62) or phenyl, from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(63)R(64); 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; 4, 5, 6, 7 or 8 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; group can be replaced by oxygen, S, NH, N-CH.sub.3, N-benzyl or N-(p-chlorophenyl); atoms, substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, CF.sub.3, methyl, methoxy and NR(63)R(64); hydrogen; or a pharmaceutically tolerable salt thereof; ##STR185## in which: R(1) is H, F, Cl, Br, I, CN, NO.sub.2, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy having 3, 4, 5, 6, 7 or 8 carbon atoms or X.sub.a --(CH.sub.2).sub.b --(CF.sub.2).sub.c --CF.sub.3 ; R(6); biphenylyl or naphthyl, are substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); atoms; atoms in the cycloalkyl ring, heteroaryl having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms or phenyl, substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino; hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; 7, 8, or 9 carbon atoms, the latter linked via a carbon or nitrogen atom of the ring, each of which is unsubstituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, CH.sub.3, methoxy, hydroxyl, amino, methylamino and dimethylamino, --C[R(15)R(16)OH], --C=CR(18), --C[R(19)]=CHR(18), --C[R(20)R(21 )].sub.k --(CO)--[CR(22)R(23)],--R(24), --R(17) carbon atoms, or, together with the carbon atom carrying them, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms; the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); is unsubstituted or is substituted as phenyl; unsubstituted or is substituted by 1-3 OH; hydrogen or methyl; 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.m H.sub.2m --R(18); having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl, naphthyl, pyridyl or quinolinyl, or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(7)R(8); 2, 3 or 4 carbon atoms; 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, CN or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3, ##STR186## in which: R(1) is R(13)-SO.sub.m or R (14)R(15)N-SO.sub.2 --; having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.n H.sub.2n --R(16), biphenylyl or naphthyl, substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(25)R(26); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 3, 4, 5, 6, 7 or 8 carbon atoms or --C.sub.n H.sub.2n -R(27), biphenylyl or naphthyl, substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(28)R(29); 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; having 1, 2, 3 or 4 carbon atoms; CH.sub.2 group can be replaced by oxygen, S, NH, N-CH.sub.3 or N-benzyl; --CHR(30)R(31); or having 1, 2, 3 or 4 carbon atoms, carbon atoms, F, Cl, Br, I, CN or --(CH.sub.2).sub.n --(CF.sub.2).sub.o --CF.sub.3 ; ##STR187## in which: R1, R2, R3, R4, R5 and R6 independently of one another are H, C.sub.1 -C.sub.10 -alkyl; haloalkyl having 1-6 carbon atoms, O--C.sub.1 -C.sub.10 -alkyl, haloalkoxy having 1-6 carbon atoms, F, Cl, Br, I, aryl, substituted aryl, heteroaryl, substituted heteroaryl, OH, O-lower alkyl, O-aryl, O-lower alkylaryl, O-substituted aryl, O-lower alkyl-substituted aryl, O-C(=O)-C.sub.1 -C.sub.4 -alkylaryl, O-C(=O)--NH--C.sub.1 -C.sub.4 -alkyl, O-C(=O)-N(C.sub.1 -C.sub.4 -alkyl).sub.2, NO.sub.2, CN, CF.sub.3, NH.sub.2, NH--C(=O)--C.sub.1 -C.sub.4 -alkyl, NH-C(=O)-NH.sub.2, COOH, C(=O)-O-C.sub.1 -C.sub.4 -alkyl, C(=O)-NH.sub.2, C(=O)--NH--C.sub.1 -C.sub.4 -alkyl, C(=O)-N(C.sub.1 -C.sub.4 -alkyl).sub.2, C.sub.1 -C.sub.4 -COOH, C.sub.1 -C.sub.4 -alkyl-C(=O)--O--C.sub.1 -C.sub.4 -alkyl, SO.sub.3 H, SO.sub.2 -alkyl; SO.sub.2 -alkylaryl, SO.sub.2 -N-(alkyl).sub.2, SO.sub.2 -N(alkyl)(alkylaryl), C(=O)-R11, C.sub.1 -C.sub.10 -alkyl-C(=O)-R11, C.sub.2 -C.sub.10 -alkenyl-C(=O)-R11, C.sub.2 -C.sub.10 -alkynyl-C(=O)-R11, NH--C(=O)--C.sub.1 -C.sub.10 -alkyl-C(=O)-R11 or O-C.sub.1 -C.sub.11 -alkyl-C(=O)-R11; substituted aryl, NH.sub.2, NH-C.sub.1 -C.sub.4 -alkyl, N-(C.sub.1 -C.sub.4 -alkyl).sub.2, SO.sub.3 H, SO.sub.2 -alkyl, SO.sub.2 -alkylaryl, SO.sub.2 -N-(alkyl).sub.2 or SO.sub.2 -N(alkyl)(alkylaryl); or their pharmaceutically acceptable salts; ##STR188## in which: T is ##STR189## R(A) is hydrogen, F, Cl, Br, I, CN, OH, OR(6), (C.sub.1 -C.sub.4)-alkyl, Or(CH.sub.2).sub.a C.sub.b F.sub.2b+1, (C.sub.3 -C.sub.6)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(9)R(10); -C.sub.4)-perfluoro-alkyl; group can be replaced by oxygen, sulfur, NH, N-CH.sub.3 or N-benzyl; OP(CH.sub.2).sub.f C.sub.g F.sub.2g+1, (C.sub.3 -C.sub.8)-cycloalkyl or (C.sub.1 -C.sub.9)-heteroaryl; (C.sub.3 -C.sub.8)-alkenyl, (C.sub.3 -C.sub.8)-cycloalkyl, phenyl or benzyl, the phenyl nucleus not being substituted or being substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy and NR(13)R(14); -C.sub.4)-perfluoroalkyl; C.sub.q F.sub.2q+1, F, Cl, Br, I, CN, --(C=O)--N=C(NH.sub.2).sub.2, --So.sub.r R(17), --So.sub.r2 NR(31)R(32), --O.sub.u (CH.sub.2).sub.v C.sub.6 H.sub.5, --O.sub.u2 --(C.sub.1 -C.sub.9)-heteroaryl or --S.sub.u2 -(C.sub.1 -C.sub.9)-heteroaryl; -C.sub.8)-alkyl or (C.sub.1 -C.sub.8)-perfluoroalkyl; CH.sub.2 group can be replaced by oxygen, S, NH, N-CH.sub.3 or N-benzyl; substituents selected from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w NR(21)R(22), NR(18)R(19) and (C.sub.1 -C.sub.9)-heteroaryl; -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-perfluoroalkyl; or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.sub.3, methyl or methoxy; from the group consisting of F, Cl, CF.sub.3, methyl, methoxy, --(CH.sub.2).sub.w2 NR(24)R(25) and NR(26)R(27); -C.sub.4)-perfluoroalkyl; times at most; ##STR190## in which: R(1) is CF.sub.3 ; --C(OH)(CH.sub.3)--CH.sub.2 OH, --CH(CH.sub.3)--CH.sub.2 OH or --C(OH)(CH.sub.3).sub.2 ; ##STR191## in which: W, Y and Z CF.sub.3, --C.sub.2 F.sub.5, --CN, --NO.sub.2, --ethynyl, or an X--R'; -C.sub.8)-cycloalkylalkyl, CF.sub.3, CH.sub.2 F, CHF.sub.2, CH.sub.2 -CF.sub.3, Ph, --CH.sub.2 -Ph or Het; or trisubstituted by A, OA, NR'R", Hal, CF.sub.3 ; having 1 to 4 nitrogen, oxygen and/or sulfur atoms, OH, OA, --X--R', --CN, --NO.sub.2, and/or carbonyl oxygen, m=zero to 6; can also be replaced by oxygen, S, NH, N--A, N--Ph and N--CH.sub.2 --Ph; X--R', --C(=N--OH)--A, A--O--CO--(C.sub.1 -C.sub.4)-alkyl--, CN, NO.sub.2, COOH, halogen-substituted A, in particular CF.sub.3, CH.sub.2 F, CHF.sub.2, C.sub.2 F.sub.5, CH.sub.2 CF.sub.3, or S(O).sub.n R'"; --O--CH.sub.2 --Ph, --CO--A, --CHO, --COOA, --CSNR'R", CONR'R", --CH=CH--COOH, --CH=CH--COOA, indenyl, indanyl, decahydronaphthyl, cyclopentenyl, dihydrothienyl, dihydrofuryl, heterobicyclyl, alkylthienyl, halothienyl, haloalkylthienyl, acylthienyl, halofuryl, haloalkylfuryl or pyrrolyl; -C.sub.7)-cycloalkyl; ##STR192## or two of the substituents R(1) to R(4) together are a group --O--CR(6)R(7)--CO--NR(8)--, ##STR193## where R(2) has the meaning indicated; R(6), R(7), R(8) and R(9) independently of one another are H or A; -C.sub.8)-cycloalkyl, Het; ##STR194## in which R(2) is hydrogen, unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, OH, (C.sub.1 -C.sub.6)-alkyl--O--, an aromatic radical or a group --CH.sub.2 --R(20); unsubstituted or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.2 -C.sub.6)-alkynyl, (C.sub.3 -C.sub.7)-cycloalkyl, halogen, --NO.sub.2, (C.sub.2 -C.sub.8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, --COOH, (C.sub.2 -C.sub.6)-alkoxycarbonyl, an aromatic group or one of the following mentioned groups: --OR(3), --NR(6)R(7) or --S(O).sub.n R(40); -C.sub.8)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, an aromatic radical or a group --CH.sub.2 --R(30); substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, (C.sub.2 -C.sub.8)-alkanoyl, an arylalkanoyl group having up to 10 carbon atoms, an aroyl group having up to 11 carbon atoms, an aromatic group or --CH.sub.2 --R(60); amine, which can additionally contain further heteroatoms in the ring; aromatic group, or a group ##STR195## A is oxygen , --S(O).sub.n -- or --N(R50)--; R(50) is hydrogen or (C.sub.1 -C.sub.8)-alkyl; which the ring represents a saturated 3-8-membered heterocycle having a nitrogen atom, consisting of halogen, --OH, (C.sub.1 -C.sub.6)-alkoxy, --CN, --COOH, (C.sub.2 -C.sub.6)-alkoxycarbonyl, (C.sub.2 -C.sub.8)-alkanoyl, arylalkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, --CONR(4)(R5), cyclic amine which can additionally contain further heteroatoms in the ring, ##STR196## in which: E is a nitrogen atom or a CH group; substituted by OH or substituted (C.sub.1 -C.sub.8)-alkyl, (C.sub.1 -C.sub.6)-alkoxy, --CN, --COOH, (C.sub.2 -C.sub.6)-alkoxycarbonyl, (C.sub.2 -C.sub.8)-alkanoyl, aralkanoyl having up to 10 carbon atoms, aroyl having up to 11 carbon atoms, an aromatic group, --NR(6)R(7), --CONR(4)R(5); ##STR197## is a 3-8-mebered saturated aliphatic or heterocyclic ring system having a nitrogen atom, and where the aromatic groups mentioned are an aryl radical having up to 10 carbon atoms, a 5- or 6-membered heteroaryl radical having 1-4 nitrogen atoms, a 5- or 6-membered heteroaryl group containing 1 or 2 nitrogen atoms and a heteroatom which is oxygen or sulfur, or furyl, and where the aryl radicals mentioned can be unsubstituted or substituted by unsubstituted (C.sub.1 -C.sub.8)-alkyl or substituted (C.sub.1 -C.sub.8)-alkyl, halogen, --NO.sub.2, (C.sub.2 -C.sub.6)-alkoxycarbonyl, COOH, --OR(3), NR(6)R(7), --CONR(4)R(5), --SO.sub.2 NR(6)R(7) or S(O).sub.n R(40), where R(1) and the guanidinocarbonyl radical can be in any desired position of the 5- or 6-membered ring of the indole system, ##STR198## in which: X is --O--, --S--, --NH--, --N[(C.sub.1 -C.sub.4)-alkyl]-- or --N(phenyl)--; (C.sub.1 -C.sub.4)-alkyl--O--, phenyl, benzyl; ring; -C.sub.12)-alkyl, benzhydryl, aralkyl, groups halogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkyl--O-- or --CF.sub.3, --(CH.sub.2).sub.m --CH.sub.2 --T, ##STR199## a pyrazole or imidazole ring of the formula ##STR200## a naphthyl radical or a dihydro- or tetrahydronaphthyl radical ##STR201## a 2-, 3- or 4-pyridyl radical ##STR202## Z is N-- or CH; a thienyl radical ##STR203## R(6) is hydrogen, halogen, hydroxyl, (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.10)-alkyl--O--, phenoxy, (C.sub.1 -C.sub.10)-alkyloxymethyloxy- or --(O).sub.n S--R(9); thiadiazolyl, imidazolyl, pyrazolyl or phenyl, (C.sub.1 -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-alkyl--O--; (C.sub.1 -C.sub.10)-alkyl--O--, phenyl, phenoxy or (C.sub.1 -C.sub.10)-alkoxymethyloxy; -C.sub.4)-alkyl or (C.sub.1 -C.sub.4)-alkyl--O--; R(13)R(14)-- or --R(15)--; imidazolyl or pyrazolyl; -C.sub.4)-alkyl; ring; unsubstituted or substituted by --COOH, (C.sub.1 -C.sub.5)-alkoxycarbonyl, (C.sub.2 -C.sub.4)-hydroxylalkylene or benzyl; tetrahydropyridyl, quinuclidinyl, imidazolyl, 3-azabicyclo[3.2.1]octyl, which is unsubstituted or substituted by (C.sub.1 -C.sub.4)-alkyl, ##STR204## R(16) is hydrogen, (C.sub.1 -C.sub.4)-alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, phenyl, tolyl, methoxyphenyl, halophenyl, diphenylmethylene, benzyl or pyridyl; '-N.sub.3 ; ##STR205## where R1=R2 is H, halo, alkyl, CN, NO.sub.2, perfluoroalkyl, SO.sub.n CF.sub.3 ; R3 is CH=CH.sub.2, CH.sub.2 --CH=CH.sub.2, CH.sub.2 --CH.sub.2 --CH=CH.sub.2, cycloalkenyl, cycloalkenylalkyl; R4 is alkyl, (substituted) phenyl.